var title_f37_63_38896="D latum egg iodine stain";
var content_f37_63_38896=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F50301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F50301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diphyllobothrium latum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The egg of D. latum is visible in a stool specimen stained with iron.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Figure contributed by Georgia Division of Public Health. file://www.dpd.cdc.gov/dpdx/HTML/ImageLibrary/Diphyllobrothiasis_il.html (Centers for Disease Control and Prevention, National Center for Infectious Diseases, Division of Parasitic Diseases. Public domain).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_63_38896=[""].join("\n");
var outline_f37_63_38896=null;
var title_f37_63_38897="Hexylresorcinol: Drug information";
var content_f37_63_38897=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hexylresorcinol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F179146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Sucrets&reg; Original [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F179153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiseptic, Topical;",
"     </li>",
"     <li>",
"      Local Anesthetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F179147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Sore throat:",
"     </b>",
"     Oral: Lozenge: One lozenge every 2 hours as needed (maximum: 10 lozenges/day)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F179152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Sore throat:",
"     </b>",
"     Oral: Children &ge;6 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F179148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F179140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lozenge, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sucrets&reg; Original: 2.4 mg (18s) [mint flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F179133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F11511763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Allow lozenge to dissolve slowly.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F179141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Minor antiseptic and local anesthetic for sore throat; topical antiseptic for minor cuts or abrasions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F179143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to hexylresorcinol or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F179136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sore throat (self-medication, OTC use): When self-medicating, patients should be instructed to contact healthcare provider if symptoms last &gt;7 days; when treating a severe sore throat, patients should contact healthcare provider if symptoms lasts &gt;2 days and if accompanied by fever, rash, nausea, or vomiting; or if symptoms worsen.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Nyal Medithroat Anaesthetic Lozenges (AU);",
"     </li>",
"     <li>",
"      Oxana (IT)",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8972 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-14B9D587E9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_63_38897=[""].join("\n");
var outline_f37_63_38897=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179146\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179153\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179147\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179152\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179148\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179140\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179133\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11511763\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179141\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179143\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179136\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299446\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220797\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539875\">",
"      International Brand Names",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8972\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8972|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_63_38898="Chlamydia urethral Gram stain";
var content_f37_63_38898=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F56547&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F56547&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gram stain of urethral discharge",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 268px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Polymorphonuclear leukocytes without intracellular pathogens are characteristic of the mucopurulent discharge seen in men with chlamydial infection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from the Centers for Disease Control and Prevention.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_63_38898=[""].join("\n");
var outline_f37_63_38898=null;
var title_f37_63_38899="Nephrology pattern 13";
var content_f37_63_38899=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F57678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F57678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nephrology pattern 13",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 255px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_63_38899=[""].join("\n");
var outline_f37_63_38899=null;
var title_f37_63_38900="Urinary sediment in acute tubular necrosis";
var content_f37_63_38900=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F56438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F56438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Photomicrograph showing urine sediment with muddy brown granular casts",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Urine sediment showing multiple muddy brown granular casts. These findings are highly suggestive of acute tubular necrosis in a patient with acute renal failure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harvard Medical School.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_63_38900=[""].join("\n");
var outline_f37_63_38900=null;
var title_f37_63_38901="Mobilization and transection of the esophagus";
var content_f37_63_38901=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F71227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F71227&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 490px\">",
"   <div class=\"ttl\">",
"    Mobilization and transection of the esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 470px; height: 712px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The esophagus is encircled with a penrose drain and the crus of the diaphragm is taken down bilaterally. Following skeletonization of the distal esophagus, four stay sutures of 2-0 Prolene are placed circumferentially in the esophagus approximately 2 cm proximal to the presumed gastroesophageal junction. An automatic pursestringer and circular stapling device and knife are used to transect the distal esophagus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_63_38901=[""].join("\n");
var outline_f37_63_38901=null;
var title_f37_63_38902="Schematic of allantoic cyst";
var content_f37_63_38902=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58326&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58326&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 611px\">",
"   <div class=\"ttl\">",
"    Schematic drawing of an expanding allantoic cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 591px; height: 362px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Primitive umbilical cord with midgut herniation, umbilical vein (in blue), umbilical artery (in red), and the urachus (in yellow).",
"    <br>",
"     (B) When the urachus remains patent, an allantoic cyst (ac) develops in the center of the umbilical vessels.",
"     <br>",
"      (C) The expanding allantoic cyst (ac) will push the vessels to the periphery.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_63_38902=[""].join("\n");
var outline_f37_63_38902=null;
var title_f37_63_38903="Occupational asthma: Pathogenesis";
var content_f37_63_38903=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Occupational asthma: Pathogenesis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/63/38903/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/63/38903/contributors\">",
"     Moira Chan-Yeung, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/63/38903/contributors\">",
"     Louis-Philippe Boulet, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/63/38903/contributors\">",
"     Jean-Luc Malo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/63/38903/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/63/38903/contributors\">",
"     Peter J Barnes, DM, DSc, FRCP, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/63/38903/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/63/38903/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/63/38903/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The label \"asthma in the workplace\" encompasses several entities: (1) asthma exacerbated at work by various environmental conditions; (2) occupational asthma; and (3) variants (eg, eosinophilic bronchitis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/1\">",
"     1",
"    </a>",
"    ]. Occupational asthma is a disease characterized by variable airflow limitation, airway hyperresponsiveness, and inflammation resulting from an inciting agent only found in the workplace [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis and pathology of occupational asthma will be reviewed here. Issues related to other aspects of occupational asthma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/0/34824?source=see_link\">",
"     \"Occupational asthma: Definitions, epidemiology, causes, and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/15/36089?source=see_link\">",
"     \"Occupational asthma: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/28/8650?source=see_link\">",
"     \"Reactive airways dysfunction syndrome and irritant-induced asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three main types of occupational asthma have been recognized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunologically mediated with participation of specific IgE",
"     </li>",
"     <li>",
"      Immunologically mediated without evidence of participation of IgE",
"     </li>",
"     <li>",
"      Nonimmunologic, irritant mediated, also known as sensitizer induced. This type includes reactive airways dysfunction syndrome (RADS) caused by a single high level exposure to an irritant and also chronic lower level exposure. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/28/8650?source=see_link\">",
"       \"Reactive airways dysfunction syndrome and irritant-induced asthma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some occupational agents, such as diisocyanates, may induce asthma through more than one mechanism. As an example, asthma may develop in subjects after a diisocyanate spill by causing acute airway injury and reactive airways dysfunction syndrome (RADS), while in others, sensitization to diisocyanate develops with lower levels of exposure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/28/8650?source=see_link\">",
"     \"Reactive airways dysfunction syndrome and irritant-induced asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the case of immunologically mediated occupational asthma, the pathology in the airways at the time of exposure is similar to that seen in patients with nonoccupational asthma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/52/4937?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathogenesis of asthma\", section on 'Airway inflammation'",
"    </a>",
"    .) Nonimmunologic irritant mediated occupational asthma is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/28/8650?source=see_link\">",
"     \"Reactive airways dysfunction syndrome and irritant-induced asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathologic abnormalities associated with occupational asthma persist for weeks to years after cessation of exposure. One study examined the bronchial biopsies of 18 subjects with occupational asthma after cessation of exposure for a period of 3 to 24 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/3\">",
"     3",
"    </a>",
"    ]. Eleven subjects had disease due to exposure to high molecular weight compounds, and seven to low molecular weight (LMW) compounds. Extensive epithelial desquamation, epithelial cell ciliary abnormalities, smooth muscle hyperplasia, and subepithelial fibrosis were found, and the numbers of total inflammatory cells, eosinophils, and lymphocytes were increased compared to healthy controls (",
"    <a class=\"graphic graphic_picture graphicRef60266 \" href=\"mobipreview.htm?36/32/37383\">",
"     picture 1",
"    </a>",
"    ). Similar findings were described in reports of subjects with isocyanate- and Western red cedar-related asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subjects with isocyanate-induced asthma show a reduction in subepithelial fibrosis, but persistence of inflammatory cell infiltration of the airways after removal from exposure for a period ranging from 5 to 21 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/6\">",
"     6",
"    </a>",
"    ]. The course of airway hyperresponsiveness parallels that of airway inflammation, suggesting that airway inflammation contributes to the persistence of hyperresponsiveness.",
"   </p>",
"   <p>",
"    Persistent airway inflammation and remodeling exists even in patients whose occupational asthma is presumed to be cured. In an observational study, 133 patients with occupational asthma were evaluated at a mean of nine years after cessation of the exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/7\">",
"     7",
"    </a>",
"    ]. Among those patients from whom induced sputum was obtained (n=84), eosinophils were detected in 18 percent and greater than 61 percent neutrophils were detected in 45 percent. Ten patients with entirely normal airway caliber, airway responsiveness, and levels of induced sputum cells, underwent bronchoscopy with bronchial biopsies at a mean of 14 years after cessation of exposure. Compared to controls, patients with prior occupational asthma had more transforming growth factor (TGF)-beta1 and eosinophil cationic protein (ECP) positive cells, increased subepithelial fibrosis, and decreased distance between the epithelium and airway smooth muscle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/8\">",
"     8",
"    </a>",
"    ]. These findings suggest that permanent inflammatory and structural changes persist many years after stopping exposure to an antigenic material.",
"   </p>",
"   <p>",
"    Acute changes in the airways of subjects with RADS or irritant-induced asthma consist of rapid denudation of the mucosa with fibrinohemorrhagic exudate in the submucosa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/9\">",
"     9",
"    </a>",
"    ]. This is followed by regeneration of the epithelium with proliferation of basal and parabasal cells, subepithelial edema, and marked thickening of the airway wall (",
"    <a class=\"graphic graphic_picture graphicRef53602 graphicRef62311 \" href=\"mobipreview.htm?39/63/40954\">",
"     picture 2A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/10\">",
"     10",
"    </a>",
"    ]. Similar findings have been described in an animal model of RADS due to chlorine exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. In irritant-induced asthma due to multiple exposures to an irritant, an inflammatory infiltrate with eosinophils and lymphocytes is found, as well as diffuse deposition with collagen fibers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/13\">",
"     13",
"    </a>",
"    ]. Even many years after the inhalational accident, induced sputum has increased levels of mediators involved in inflammation and remodeling. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/28/8650?source=see_link\">",
"     \"Reactive airways dysfunction syndrome and irritant-induced asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genes involved in susceptibility to occupational asthma are largely the same as those involved in non-occupational asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Innate immunity and immunoregulation",
"     </li>",
"     <li>",
"      Th2-cell differentiation",
"     </li>",
"     <li>",
"      Epithelial biology and mucosal immunity",
"     </li>",
"     <li>",
"      Lung function (airway hyperresponsiveness), airway remodeling, and disease severity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies of genes involved in immunoregulation have shown associations between HLA Class-2 antigens and various types of occupational asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/15\">",
"     15",
"    </a>",
"    ]. The associations with HLA antigens have biological implications in that they provide evidence for a specific immunological response and for T cell involvement in the development of occupational asthma caused by low molecular weight compounds.",
"   </p>",
"   <p>",
"    Genes involved in airway remodeling, such as glutathione S-transferase (GSTP1 and GSTM1) and N-acetyltransferase (NAT1), may participate in the development of occupational asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glutathione S-transferase belongs to a family of enzymes that detoxify chemical substances in the body. Homozygosity for the GSTP1*Val allele provides a protective effect against asthma in workers exposed to isocyanate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/2,16\">",
"       2,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      N-acetyltransferase also helps to metabolize drugs and chemicals. The slow acetylator genotype increases the risk of asthma in workers exposed to toluene diisocyanate (TDI) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/2,17\">",
"       2,17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     IMMUNOLOGIC MECHANISMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Agents that induce occupational asthma by immunologic mechanisms are characterized by a latency period between exposure and the development of symptoms. Immunologic occupational asthma affects only a small proportion of exposed subjects, but in these patients exposure to a minute quantity of the offending agent can lead to a severe asthmatic reaction. While some compounds, mostly metal salts and those containing protein, induce asthma through the production of specific IgE antibodies, the immunologic mechanism(s) that pertain to other agents (most chemicals) have not been identified.",
"   </p>",
"   <p>",
"    High-molecular-weight agents most commonly cause IgE-mediated occupational asthma in atopic subjects. In contrast, low molecular weight agents are more likely to cause non-IgE-mediated disease in nonatopic subjects and nonsmokers. Although atopy is associated with occupational asthma due to high-molecular-weight agents, the intensity of exposure to the high molecular agent is the most important determinant of the disease.",
"   </p>",
"   <p>",
"    The most common route of exposure in occupational asthma is inhalational. However, skin exposure has also been incriminated in the onset of sensitization to diisocyanates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     IgE-mediated",
"    </span>",
"    &nbsp;&mdash;&nbsp;High molecular weight (HMW) agents (eg, latex, animal proteins, and flour) act as complete antigens and induce the production of specific IgE antibodies. Certain low molecular weight (LMW) occupational agents, including platinum salts, trimellitic anhydride, and other acid anhydrides, can also induce specific IgE antibodies, probably by acting as haptens and binding with proteins to form functional antigens (",
"    <a class=\"graphic graphic_table graphicRef66185 \" href=\"mobipreview.htm?27/53/28508\">",
"     table 1",
"    </a>",
"    ). These agents mostly affect atopic subjects. Several HLA associations have been described, but the results have not been convincingly reproduced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Regardless of the characteristics of the inciting antigen, reactions between specific IgE antibodies and antigens lead to a cascade of events that results in an influx of inflammatory cells into the airway and the release of inflammatory mediators.",
"   </p>",
"   <p>",
"    Inhalational challenge with culprit antigens in sensitized individuals generally results in an isolated early reaction, although inhalation challenge may sometimes result in a late reaction or a biphasic reaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An isolated early asthmatic reaction occurs within a few minutes after an inhalation challenge, reaches it maximum within one-half hour, and subsides within 1 to 1.5 hours.",
"     </li>",
"     <li>",
"      A late reaction occurs four to six hours after a challenge, reaches maximal intensity within eight to ten hours, and subsides after 24 to 48 hours (",
"      <a class=\"graphic graphic_figure graphicRef56482 \" href=\"mobipreview.htm?9/47/9983\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A biphasic reaction is a combination of an early and a late reaction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific inhalation challenges can also cause atypical temporal patterns of airflow limitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Detection of IgE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability to detect specific IgE antibodies in patients with occupational asthma to low molecular weight agents may be technically difficult [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Specific IgE antibodies to toluene diisocyanate (TDI) have been reported in 0 to 50 percent of workers with TDI induced asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/23\">",
"     23",
"    </a>",
"    ]. This variation has been attributed to several factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The short half-life of the specific IgE antibodies to TDI of about two days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/24\">",
"       24",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The appearance of new antigenic determinants after the binding of specific IgE to TDI-human albumin conjugate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/25\">",
"       25",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Use of different carrier proteins. As an example, human serum albumin is sometimes used for conjugation with TDI, while keratin, which is found in the lungs and skin, has been found to conjugate with hexamethylene diisocyanate in studies using human epithelial cell lines and endobronchial biopsy samples [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/26\">",
"       26",
"      </a>",
"      ]. Whether the TDI-keratin conjugate would give a higher proportion of specific IgE antibodies in patients with TDI induced asthma remains to be seen.",
"     </li>",
"     <li>",
"      The different methods of conjugation of the haptenic low molecular weight antigen with a carrier and the methods of assay [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pathogenic mechanisms other than IgE mediation are causing occupational asthma. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Non-IgE mediated reactions'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Non-IgE mediated reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many low molecular weight (LMW) agents can induce occupational asthma after a latent period (eg, acid anhydrides, certain metals, diisocyanates), suggestive of immunologic mediation. Some LMW agents produce pathogenic IgE via conjugation with a hapten (see",
"    <a class=\"local\" href=\"#H6\">",
"     'IgE-mediated'",
"    </a>",
"    above). However, many LMW agents are NOT associated with production of specific IgE. The exact nature of the non-IgE immunologic mechanisms remains unclear.",
"   </p>",
"   <p>",
"    The ability of a LMW agent to induce asthma may depend upon its chemical structure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. As examples, certain transitional metals form coordination complexes that may chelate human proteins (eg, chromium, cobalt, nickel, platinum), and some organic substances have two or more reactive chemical groups (eg, amines, cyanates) that are highly reactive with human macromolecules. The agents with two or more reactive chemical groups, also known as bifunctional bases, (eg, diisocyanate) have a much higher propensity to induce asthma than those with a single reactive group, also known as a monofunctional base (eg, monoisocyanates) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Evidence against IgE mediation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence against IgE mediation in occupational asthma induced by LMW agents includes the following observations: affected workers are typically nonatopic, the pattern of airflow limitation following inhalational challenge is different from that of IgE-mediated occupational asthma, and the IgE molecules identified lack the ability to cause passive sensitization.",
"   </p>",
"   <p>",
"    Specific inhalation challenge tests with these agents generally induce an isolated late asthmatic reaction or a biphasic reaction, rather than the predominantly early reaction of IgE mediated occupational asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/20\">",
"     20",
"    </a>",
"    ]. A continuous asthmatic reaction with no remission between the early and the late phases is occasionally induced, and an atypical reaction starting two hours after a challenge and lasting for several hours has also been described (",
"    <a class=\"graphic graphic_figure graphicRef65163 \" href=\"mobipreview.htm?30/21/31070\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/4/1098?source=see_link&amp;anchor=H26846610#H26846610\">",
"     \"Bronchoprovocation testing\", section on 'Antigen challenge'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with occupational asthma due to non-IgE mediated reactions may produce IgE antibodies that are reflective of prior exposure, rather than being integral to disease pathogenesis. As an example, Western red cedar-related asthma, caused by sensitization to the LMW agent plicatic acid, results in production of IgE antibodies to plicatic acid in approximately 20 percent of affected subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/29\">",
"     29",
"    </a>",
"    ]. However, these antibodies do not passively sensitize human lung fragments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Based on the high proportion of patients without evidence of specific IgE production and the lack of passive sensitization, it is likely that non-IgE mechanisms are responsible for the majority of plicatic acid-induced occupational asthma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Evidence for cell mediated responses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies have found that cellular mediated immunological mechanisms contribute to the pathogenesis of non-IgE mediated immunologic (low molecular weight antigen) occupational asthma. Bronchial biopsies from subjects with isocyanate and red cedar-related asthma show large numbers of activated T lymphocytes adjacent to bronchi, suggesting that these cells play a direct role in mediating airway inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diisocyanate-induced asthma, a non-IgE mediated disease, appears to be associated with increased recruitment and activation of pulmonary lymphocytes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Monocyte chemoattractant protein-1, a T cell chemoattractant, is elaborated in increased amounts by peripheral blood mononuclear cells from patients with occupational asthma due to diisocyanates [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/31\">",
"       31",
"      </a>",
"      ]. Among workers exposed to diisocyanate, production of monocyte chemoattractant protein-1 (MCP-1) by peripheral blood mononuclear cells in response to stimulation with diisocyanate-human serum albumin (DIISO-HSA) was more sensitive and specific for diisocyante-induced asthma than serum levels of specific IgE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      When bronchial biopsy specimens were obtained by fiberoptic bronchoscopy 24 hours after diisocyanate inhalational challenge, bronchial recruitment of interleukin (IL)-5, CD25 (soluble IL-2 receptor), and CD4 positive cells was noted in patients with diisocyanate-induced asthma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast to most studies that suggest mediation by CD4 T cells, one study of bronchial biopsies from patients with diisocyanate-induced asthma found that the majority of T cells exhibited the CD8 phenotype and produced IFN-gamma and IL-5, with very few clones producing IL-4 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/33\">",
"       33",
"      </a>",
"      ]. However, there was evidence of an eosinophilic involvement.",
"     </li>",
"     <li>",
"      In another study, bronchial biopsies of workers with occupational asthma to methylene diphenyl diisocyanate (MDI) demonstrated an increase in eosinophil cationic protein and increased basophil release of histamine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/34\">",
"       34",
"      </a>",
"      ]. Sputum eosinophil counts correlated with IL-8 and MMP-9 levels.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other evidence that T lymphocytes play a role in the occupational asthma induced by LMW compounds comes from studies of peripheral blood cells. As an example, in patients with asthma associated with Western red cedar, nickel, or cobalt, proliferation of peripheral blood lymphocytes occurs following incubation with the appropriate antigen, suggesting the presence of a cell-mediated hypersensitivity reaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. In isocyanate-induced asthma, CD8 T cells and eosinophils are increased in the peripheral blood of subjects during late asthmatic reactions induced by challenge with the agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/37\">",
"     37",
"    </a>",
"    ]. In patients who have asthma due to platinum salts, platinum-salt-induced lymphocyte stimulation is strongly enhanced and the frequency of circulating T cells bearing certain T cell receptors (TCRs) is increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/38\">",
"     38",
"    </a>",
"    ]. In vitro stimulation with sodium hexachloroplatinate modulates the frequencies of T cells bearing certain TCRs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Specific IgG antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific IgG antibodies may play a role in low molecular weight agent-induced occupational asthma, although their exact role is unknown. As an example, specific IgG antibodies have been identified in patients with occupational asthma due to diisocyanates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Animal models",
"    </span>",
"    &nbsp;&mdash;&nbsp;Animal models have been developed to examine the physiopathology of immunologic occupational asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/39\">",
"     39",
"    </a>",
"    ]. Unique effector mechanisms may exist for different antigens or types of antigens (haptens versus protein antigens) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/9\">",
"     9",
"    </a>",
"    ]. The species, strain, age, dose of allergen, and routes of sensitization and challenge may influence the model. Effector mechanisms may also differ depending on the asthmatic reaction being considered (ie, airway obstruction or eosinophil infiltration).",
"   </p>",
"   <p>",
"    Data suggest that Th2 cytokines may play an important role in some forms of occupational asthma:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a rat model of occupational asthma, after a short period of repeated exposures to toluene diisocyanate (TDI), an inflammatory response developed, characterized by marked eosinophil infiltration of the airways and an increased production of IL-4 compared to controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hexamethylene diisocyanate (HDI)-mediated respiratory inflammatory responses in mice are mediated by CD4 positive Th2 cells although CD8 positive T lymphocytes may also play a regulatory role [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/41\">",
"       41",
"      </a>",
"      ]. Whether CD8 positive T cells play a central role in HDI-induced airway inflammation without the production of IgE antibodies has yet to be confirmed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     NONIMMUNOLOGIC MECHANISMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Agents that induce asthma by nonimmunologic mechanisms are characterized by the absence of a latency period. Three mechanisms may explain the development of symptoms in these patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subjects without any prior respiratory difficulties develop symptoms of asthma within a few hours of acute, high level irritant exposure, and may have evidence of nonallergic airway hyperresponsiveness for more than three months. Acute airway injury from accidental exposure to high dose of irritants such as chlorine, ammonia, smoke, or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19011?source=see_link\">",
"       acetic acid",
"      </a>",
"      may lead to RADS. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/28/8650?source=see_link\">",
"       \"Reactive airways dysfunction syndrome and irritant-induced asthma\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The underlying mechanism of RADS is not known, but it has been postulated that extensive denudation of the epithelium results in airway inflammation because of a loss of epithelial derived relaxing factors, exposure of the nerve endings leading to neurogenic inflammation, and nonspecific activation of mast cells with release of inflammatory mediators and cytokines [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/42\">",
"       42",
"      </a>",
"      ]. Epithelial damage may also result in the marked airway remodeling observed in these patients, particularly the intense subepithelial fibrosis which is probably responsible for the reduced reversibility of airflow obstruction observed in this condition [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some low molecular weight agents have pharmacologic properties that may cause bronchoconstriction. As examples, isocyanates may block beta-2 adrenergic receptors, and plicatic acid in high concentrations may activate complement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/44,45\">",
"       44,45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Isocyanates and other occupational agents may stimulate sensory nerves to release substance P and other neuropeptides and may inhibit the neutral endopeptidases that normally inactivate these substances [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/46\">",
"       46",
"      </a>",
"      ]. Neuropeptides affect a variety of cells in the airways, resulting in cough, smooth muscle contraction, and mucus production [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some agents can induce asthma through both immunological and nonimmunological mechanisms. Diisocyanate is the best example. Toluene diisocyanate-induced asthma (through sensitization) has been reported in individuals who have previously been heavily exposed during a chemical spill [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38903/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Occupational asthma is a disease characterized by variable airflow limitation, airway hyperresponsiveness, and inflammation resulting from exposures to agents present only in the workplace. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Three main types of occupational asthma have been recognized: immunologically mediated with participation of specific IgE, immunologically mediated without evidence of participation of IgE, and nonimmunologic, irritant mediated. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Types'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the case of immunologically mediated occupational asthma, the pathology in the airways is similar to that seen in patients with nonoccupational asthma. The pathologic changes may persist for weeks to years after cessation of exposure. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      High molecular weight agents (eg, animal proteins and flour) act as complete antigens and induce the production of specific IgE antibodies, which are felt to play a key role in disease pathogenesis, similar to that of inhalant allergens (eg, dust mite) in allergic asthma. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Immunologic mechanisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Certain low molecular weight occupational agents, including platinum salts, trimellitic anhydride, and other acid anhydrides, also induce specific IgE antibodies, probably by acting as haptens, binding with proteins to form functional antigens. Low molecular weight agents may also cause occupational asthma through non-IgE mediated mechanisms. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Immunologic mechanisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Occupational asthma due to exposure to irritants (eg, chlorine, ammonia, smoke) may result from nonimmunologic mechanisms such as denudation of the airway epithelium, direct beta-2 adrenergic receptor inhibition, or elaboration of substance P by injured sensory nerves. Nonimmunologic occupational asthma is characterized by the absence of a latency period and, often, by a high level exposure. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Nonimmunologic mechanisms'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/28/8650?source=see_link\">",
"       \"Reactive airways dysfunction syndrome and irritant-induced asthma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Bernstein, IL, Chan-Yeung, M, Malo, JL, Berstein, DI. Asthma in the workplace, 3rd, Taylor and Francis, New York 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/2\">",
"      Maestrelli P, Boschetto P, Fabbri LM, Mapp CE. Mechanisms of occupational asthma. J Allergy Clin Immunol 2009; 123:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/3\">",
"      Boulet LP, Boutet M, Laviolette M, et al. Airway inflammation after removal from the causal agent in occupational asthma due to high and low molecular weight agents. Eur Respir J 1994; 7:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/4\">",
"      Bentley, AM, Maestrelli, et al. Immunochemistry of the bronchial mucosa in occupational, intrinsic and extrinsic asthma. J Allergy Clin Immunol 1991; 87:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/5\">",
"      Frew AJ, Chan H, Lam S, Chan-Yeung M. Bronchial inflammation in occupational asthma due to western red cedar. Am J Respir Crit Care Med 1995; 151:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/6\">",
"      Saetta M, Di Stefano A, Maestrelli P, et al. Airway mucosal inflammation in occupational asthma induced by toluene diisocyanate. Am Rev Respir Dis 1992; 145:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/7\">",
"      Maghni K, Lemi&egrave;re C, Ghezzo H, et al. Airway inflammation after cessation of exposure to agents causing occupational asthma. Am J Respir Crit Care Med 2004; 169:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/8\">",
"      Sumi Y, Foley S, Daigle S, et al. Structural changes and airway remodelling in occupational asthma at a mean interval of 14 years after cessation of exposure. Clin Exp Allergy 2007; 37:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/9\">",
"      Regal JF. Immunologic effector mechanisms in animal models of occupational asthma. J Immunotoxicol 2004; 1:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/10\">",
"      Lemi&egrave;re C, Malo JL, Boutet M. Reactive airways dysfunction syndrome due to chlorine: sequential bronchial biopsies and functional assessment. Eur Respir J 1997; 10:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/11\">",
"      Demnati R, Fraser R, Ghezzo H, et al. Time-course of functional and pathological changes after a single high acute inhalation of chlorine in rats. Eur Respir J 1998; 11:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/12\">",
"      Martin JG, Campbell HR, Iijima H, et al. Chlorine-induced injury to the airways in mice. Am J Respir Crit Care Med 2003; 168:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/13\">",
"      Chang-Yeung M, Lam S, Kennedy SM, Frew AJ. Persistent asthma after repeated exposure to high concentrations of gases in pulpmills. Am J Respir Crit Care Med 1994; 149:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/14\">",
"      Malo JL, L'archev&ecirc;que J, Castellanos L, et al. Long-term outcomes of acute irritant-induced asthma. Am J Respir Crit Care Med 2009; 179:923.",
"     </a>",
"    </li>",
"    <li>",
"     Newman-Taylor, AJ, Yucesov, B. Genetics and Occupational Asthma. In: Asthma in the Workplace, 3rd, Taylor and Francis, New York 2006. p.87.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/16\">",
"      Piiril&auml; P, Wikman H, Luukkonen R, et al. Glutathione S-transferase genotypes and allergic responses to diisocyanate exposure. Pharmacogenetics 2001; 11:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/17\">",
"      Mapp CE, Fryer AA, De Marzo N, et al. Glutathione S-transferase GSTP1 is a susceptibility gene for occupational asthma induced by isocyanates. J Allergy Clin Immunol 2002; 109:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/18\">",
"      Redlich CA, Herrick CA. Lung/skin connections in occupational lung disease. Curr Opin Allergy Clin Immunol 2008; 8:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/19\">",
"      Pepys J. New tests to assess lung function. inhalation challenge tests in asthma. N Engl J Med 1975; 293:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/20\">",
"      Perrin B, Cartier A, Ghezzo H, et al. Reassessment of the temporal patterns of bronchial obstruction after exposure to occupational sensitizing agents. J Allergy Clin Immunol 1991; 87:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/21\">",
"      Karol MH, Alarie Y. Antigens which detect IgE antibodies in workers sensitive to toluene diisocyanate. Clin Allergy 1980; 10:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/22\">",
"      Wisnewski AV, Jones M. Pro/Con debate: Is occupational asthma induced by isocyanates an immunoglobulin E-mediated disease? Clin Exp Allergy 2010; 40:1155.",
"     </a>",
"    </li>",
"    <li>",
"     Wisnewski, A, Redlich, CA, Mapp, CE, Bernstein, DI. Polyisocyanates and their Prepolymers. In: Asthma in the workplace, 3rd, Bernstein, IL, Chan-Yeung, M, Malo, JL, Bernstein, DI (Eds), Taylor and Francis, New York 2006. p.481.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/24\">",
"      Tee RD, Cullinan P, Welch J, et al. Specific IgE to isocyanates: a useful diagnostic role in occupational asthma. J Allergy Clin Immunol 1998; 101:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/25\">",
"      Park HS, Kim HY, Lee SK, et al. Diverse profiles of specific IgE response to toluene diisocyanate (TDI)-human serum albumin conjugate in TDI-induced asthma patients. J Korean Med Sci 2001; 16:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/26\">",
"      Wisnewski AV, Lemus R, Karol MH, Redlich CA. Isocyanate-conjugated human lung epithelial cell proteins: A link between exposure and asthma? J Allergy Clin Immunol 1999; 104:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/27\">",
"      Agius RM. Why are some low-molecular-weight agents asthmagenic. Occup Med 2000; 15:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/28\">",
"      Jarvis J, Seed MJ, Elton R, et al. Relationship between chemical structure and the occupational asthma hazard of low molecular weight organic compounds. Occup Environ Med 2005; 62:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/29\">",
"      Frew A, Chan H, Dryden P, et al. Immunologic studies of the mechanisms of occupational asthma caused by western red cedar. J Allergy Clin Immunol 1993; 92:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/30\">",
"      Tse KS, Chan H, Chan-Yeung M. Specific IgE antibodies in workers with occupational asthma due to western red cedar. Clin Allergy 1982; 12:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/31\">",
"      Bernstein DI, Cartier A, C&ocirc;t&eacute; J, et al. Diisocyanate antigen-stimulated monocyte chemoattractant protein-1 synthesis has greater test efficiency than specific antibodies for identification of diisocyanate asthma. Am J Respir Crit Care Med 2002; 166:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/32\">",
"      Jones MG, Floyd A, Nouri-Aria KT, et al. Is occupational asthma to diisocyanates a non-IgE-mediated disease? J Allergy Clin Immunol 2006; 117:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/33\">",
"      Maestrelli P, Del Prete GF, De Carli M, et al. CD8 T-cell clones producing interleukin-5 and interferon-gamma in bronchial mucosa of patients with asthma induced by toluene diisocyanate. Scand J Work Environ Health 1994; 20:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/34\">",
"      Hur GY, Sheen SS, Kang YM, et al. Histamine release and inflammatory cell infiltration in airway Mucosa in methylene diphenyl diisocyanate (MDI)-induced occupational asthma. J Clin Immunol 2008; 28:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/35\">",
"      Frew A, Chang JH, Chan H, et al. T-lymphocyte responses to plicatic acid-human serum albumin conjugate in occupational asthma caused by western red cedar. J Allergy Clin Immunol 1998; 101:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/36\">",
"      Shirakawa T, Kusaka Y, Fujimura N, et al. Hard metal asthma: cross immunological and respiratory reactivity between cobalt and nickel? Thorax 1990; 45:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/37\">",
"      Finotto S, Fabbri LM, Rado V, et al. Increase in numbers of CD8 positive lymphocytes and eosinophils in peripheral blood of subjects with late asthmatic reactions induced by toluene diisocyanate. Br J Ind Med 1991; 48:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/38\">",
"      Raulf-Heimsoth M, Merget R, Rihs HP, et al. T-cell receptor repertoire expression in workers with occupational asthma due to platinum salt. Eur Respir J 2000; 16:871.",
"     </a>",
"    </li>",
"    <li>",
"     Johnson, VJ, Luster, MI. Animal models of occupational asthma: Tools for understanding disease pathogenesis. In: Asthma in the workplace, 3rd, Bernstein, IL, Chan-Yeung, M, Malo, J-L, Bernstein, DL (Eds), Taylor and Francis, New York 2006. p.141.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/40\">",
"      Kouadio K, Zheng KC, Tuekpe MK, et al. Airway inflammatory and immunological events in a rat model exposed to toluene diisocyanate. Food Chem Toxicol 2005; 43:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/41\">",
"      Herrick CA, Das J, Xu L, et al. Differential roles for CD4 and CD8 T cells after diisocyanate sensitization: genetic control of TH2-induced lung inflammation. J Allergy Clin Immunol 2003; 111:1087.",
"     </a>",
"    </li>",
"    <li>",
"     Gautrin, D, Bernstein, IL, Brooks, SM, Henneberger, PK. Reactive Airways Dysfunction Syndrome and Irritant-Induced Asthma. In: Asthma in the Workplace, 3rd, Bernstein, IL, Chan-Yeung, M, Malo, JL, Bernstein, DI (Eds), Taylor and Francis, New York 2006. p.579.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/43\">",
"      Gautrin D, Boulet LP, Boutet M, et al. Is reactive airways dysfunction syndrome a variant of occupational asthma? J Allergy Clin Immunol 1994; 93:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/44\">",
"      Butcher BT, Karr RM, O'Neil CE, et al. Inhalation challenge and pharmacologic studies of toluene diisocyanate (TDI)-sensitive workers. J Allergy Clin Immunol 1979; 64:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/45\">",
"      Chan-Yeung M, Giclas PC, Henson PM. Activation of complement by plicatic acid, the chemical compound responsible for asthma due to western red cedar (Thuja plicata). J Allergy Clin Immunol 1980; 65:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/46\">",
"      Chitano P, Di Blasi P, Lucchini RE, et al. The effects of toluene diisocyanate and of capsaicin on human bronchial smooth muscle in vitro. Eur J Pharmacol 1994; 270:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/47\">",
"      Mapp CE, Graf PD, Boniotti A, Nadel JA. Toluene diisocyanate contracts guinea pig bronchial smooth muscle by activating capsaicin-sensitive sensory nerves. J Pharmacol Exp Ther 1991; 256:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/48\">",
"      Leroyer C, Perfetti L, Cartier A, Malo JL. Can reactive airways dysfunction syndrome (RADS) transform into occupational asthma due to \"sensitisation\" to isocyanates? Thorax 1998; 53:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38903/abstract/49\">",
"      Perfetti L, Bram&eacute; B, Ferrari M, Moscato G. Occupational asthma (OA) with sensitization to diphenylmethane diisocyanate (MDI) presenting at the onset like a reactive airways dysfunction syndrome (RADS). Am J Ind Med 2003; 44:325.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 538 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-403C6C9E42-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_63_38903=[""].join("\n");
var outline_f37_63_38903=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      IMMUNOLOGIC MECHANISMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      IgE-mediated",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Detection of IgE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Non-IgE mediated reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Evidence against IgE mediation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Evidence for cell mediated responses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Specific IgG antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Animal models",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      NONIMMUNOLOGIC MECHANISMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/538\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/538|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/47/9983\" title=\"figure 1\">",
"      Inhalation challenge testing I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/21/31070\" title=\"figure 2\">",
"      Inhalation challenge testing II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/538|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?36/32/37383\" title=\"picture 1\">",
"      Occupational asthma Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/47/18168\" title=\"picture 2A\">",
"      Irritant asthma Early",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/54/2922\" title=\"picture 2B\">",
"      Irritant asthma Late",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/538|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/53/28508\" title=\"table 1\">",
"      Causes of occupational asthma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/4/1098?source=related_link\">",
"      Bronchoprovocation testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/15/36089?source=related_link\">",
"      Occupational asthma: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/0/34824?source=related_link\">",
"      Occupational asthma: Definitions, epidemiology, causes, and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/52/4937?source=related_link\">",
"      Pathogenesis of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/28/8650?source=related_link\">",
"      Reactive airways dysfunction syndrome and irritant-induced asthma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_63_38904="Vertical growth melanoma";
var content_f37_63_38904=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F54748&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F54748&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Vertical growth phase malignant melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 566px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power photomicrographs of a nodular, vertical growth phase melanoma, characterized by the formation of an expansile nodule of melanoma cells in the dermis. Clinically, this results in a papule or nodule arising against the background of the flat radial growth phase. In the top figure (Panel A), the invasive melanoma has a polypoid growth pattern arising in a superficial spreading melanoma. The surface is ulcerated and the maximum depth of invasion is measured from the base of the ulcer to the deepest melanoma cell. In the bottom figure (Panel B), the invasive melanoma is forming large tumor nodules and has invaded the subcutis (black arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Roy King, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_63_38904=[""].join("\n");
var outline_f37_63_38904=null;
var title_f37_63_38905="Etiologies of fever of unknown origin in children";
var content_f37_63_38905=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Etiologies of fever of unknown origin in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/63/38905/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/63/38905/contributors\">",
"     Debra L Palazzi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/63/38905/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/63/38905/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/63/38905/contributors\">",
"     Robert Sundel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/63/38905/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/63/38905/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/63/38905/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/63/38905/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever is a common presenting complaint in children, accounting for nearly one-third of pediatric outpatient visits in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38905/abstract/1\">",
"     1",
"    </a>",
"    ]. The specific entity of \"fever of unknown origin\" (FUO), as opposed to a \"fever without a source\" (FWS), has occupied a special place within infectious diseases since the first definition of and series about FUO by Petersdorf and Beeson in 1961 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38905/abstract/2\">",
"     2",
"    </a>",
"    ]. Although the original definition has been modified, the assessment of broad categories of illness (including infections, connective tissue disease, and malignancy) as a cause of FUO remains useful.",
"   </p>",
"   <p>",
"    Common etiologies of FUO in children will be discussed below. The approach to the child with FUO, FWS, and fever in unique host groups (eg, newborns, neutropenic children, or those with human immunodeficiency virus [HIV] infection) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/30/9706?source=see_link\">",
"     \"Approach to the child with fever of unknown origin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/14/22762?source=see_link\">",
"     \"Fever without a source in children 3 to 36 months of age\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;We apply the term fever of unknown origin (FUO) to children with fever &gt;101&ordm;F (38.3&ordm;C) of at least eight days' duration, in whom no diagnosis is apparent after initial outpatient or hospital evaluation that includes a careful history and physical examination and initial laboratory assessment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/30/9706?source=see_link&amp;anchor=H2#H2\">",
"     \"Approach to the child with fever of unknown origin\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The number of infectious and noninfectious etiologies of fever of unknown origin (FUO) in children is extensive (",
"    <a class=\"graphic graphic_table graphicRef69379 \" href=\"mobipreview.htm?41/32/42509\">",
"     table 1",
"    </a>",
"    ). FUO is usually caused by common disorders, often with an unusual presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38905/abstract/3-13\">",
"     3-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The three most common etiological categories of FUO in children in order of frequency are infectious diseases, connective tissue diseases, and neoplasms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38905/abstract/3-13\">",
"     3-13",
"    </a>",
"    ]. In addition, there are causes of FUO, such as drug fever, factitious fever, central nervous system dysfunction, and others, that do not fit into the above categories. In many cases, a definitive diagnosis is never established and fever resolves.",
"   </p>",
"   <p>",
"    In each category below, the conditions are discussed in alphabetical order, rather than by the frequency of diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     GENERALIZED INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generalized infections that cause fever of unknown origin (FUO) typically have nonspecific presenting features. Obtaining a detailed history of exposures can be critical to making the diagnosis of these infections. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/30/9706?source=see_link&amp;anchor=H9#H9\">",
"     \"Approach to the child with fever of unknown origin\", section on 'Exposures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Brucellosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brucellosis frequently is considered in the differential diagnosis of FUO because the infection is indolent, causes nonspecific symptoms and signs, and persists if untreated. It is also often excluded as a diagnostic possibility, particularly among clinicians who practice in urban areas and may forget to consider the disease. Clinical manifestations may include persistent fever and lethargy, osteoarticular complaints and epididymoorchitis, hepatosplenomegaly, and mild elevation of liver enzymes.",
"   </p>",
"   <p>",
"    When considering the possibility of brucellosis, it is important to ask about exposure to animals or animal products, especially consumption of unpasteurized cheese",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    imported cheese (pasteurization is not required for certification of imported cheeses). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/61/33751?source=see_link\">",
"     \"Microbiology, epidemiology, and pathogenesis of Brucella\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/43/16058?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of brucellosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cat scratch disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cat scratch disease (CSD,",
"    <em>",
"     Bartonella henselae",
"    </em>",
"    infection) is one of the most common causes of FUO in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38905/abstract/10,14\">",
"     10,14",
"    </a>",
"    ]. While CSD frequently presents with isolated lymph node involvement, hepatosplenic involvement is the hallmark of CSD associated with FUO. In one series from a single institution,",
"    <em>",
"     B. henselae",
"    </em>",
"    infection accounted for 5 percent of all pediatric cases of FUO and 11 percent of the FUO cases ultimately determined to be caused by infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38905/abstract/10\">",
"     10",
"    </a>",
"    ]. High-resolution abdominal ultrasonography revealing the multiple hepatic or splenic filling defects that are characteristic of granulomata can provide a provisional diagnosis. Serology or biopsy of lesions in lymph nodes, liver, or bone marrow can lead to a definitive diagnosis of",
"    <em>",
"     B. henselae",
"    </em>",
"    infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/47/23289?source=see_link\">",
"     \"Microbiology, epidemiology, clinical manifestations, and diagnosis of cat scratch disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Leptospirosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leptospirosis is a common zoonotic infection with worldwide distribution; humans are incidental hosts, and most infection occurs in tropical climates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38905/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. The clinical manifestations are nonspecific and may include fever, rigors, myalgias, headache, cough, and gastrointestinal complaints. Leptospirosis typically occurs after exposure to environmental sources, such as animal urine, contaminated soil or water (particularly during swimming), or infected animal tissue. Portals of entry include cuts or abraded skin, mucous membranes, or conjunctiva. The infection is rarely acquired by ingestion of food contaminated with urine or via aerosols. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43879?source=see_link\">",
"     \"Microbiology, epidemiology, clinical manifestations, and diagnosis of leptospirosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/31/4597?source=see_link\">",
"     \"Treatment and prevention of leptospirosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Malaria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malaria is an important consideration in a child with FUO. Splenomegaly usually accompanies fever. Although the patient frequently has a history of travel to areas where malaria is endemic, this is not universal; rare cases have been reported in individuals who have not traveled outside of the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38905/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Malaria infection can be delayed for months after travel and can arise in those who have taken malaria prophylaxis. The diagnosis is made by examining appropriately stained thin or thick smears of blood. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/26/5543?source=see_link\">",
"     \"Clinical manifestations of malaria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/0/10248?source=see_link\">",
"     \"Diagnosis of malaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Mycobacterial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tuberculosis (TB) is another important cause of FUO in children. Extrapulmonary TB (disseminated TB, or TB of the liver, peritoneum, pericardium, or genitourinary tract), is more likely to cause FUO than pulmonary TB, which is usually evident on chest radiography. Active disseminated TB can occur in children with negative chest radiography and tuberculin skin tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38905/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. A high index of suspicion for the disease must be maintained, and a careful history of possible contacts obtained. The diagnosis of TB can be made by culturing the organism from sputum, gastric aspirates, liver, or bone marrow. Funduscopic examination occasionally can reveal choroid tubercles. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/53/13143?source=see_link\">",
"     \"Latent tuberculosis infection in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/4/23625?source=see_link\">",
"     \"Tuberculosis disease in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/21/20826?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of extrapulmonary and miliary tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nontuberculous mycobacterial infection also can cause disseminated infection and FUO, although this is more common in children infected with the human immunodeficiency virus (HIV). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/11/24759?source=see_link\">",
"     \"Overview of nontuberculous mycobacterial infections in HIV-negative patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/55/38777?source=see_link\">",
"     \"Mycobacterium avium complex (MAC) infections in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/9/15512?source=see_link\">",
"     \"Overview of nontuberculous mycobacteria (excluding MAC) in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Salmonellosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     Salmonella",
"    </em>",
"    species contaminate a number of food products, especially poultry and eggs, and can be transmitted through contact with animal feces.",
"    <em>",
"     Salmonella",
"    </em>",
"    species can cause typhoidal as well as localized gastrointestinal (GI) illness. Patients with typhoid frequently have normal pulses or even bradycardia in association with high fevers. The diagnosis can be made with blood and stool cultures, which should be repeated if initially negative and fevers persist. Serologic testing is not recommended. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/2/42024?source=see_link\">",
"     \"Epidemiology, microbiology, clinical manifestations, and diagnosis of typhoid fever\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/19/14649?source=see_link\">",
"     \"Microbiology and epidemiology of salmonellosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Toxoplasmosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxoplasmosis is another infection that can cause FUO in children. It should be considered in children with exposure to soil contaminated with feline feces, or consumption of game meat. Fevers are most often accompanied by cervical or supraclavicular lymphadenopathy, but fever may occasionally be the sole manifestation. A rise in antibody titer can establish the diagnosis; however, a single high antibody titer is not sufficient to make a diagnosis of acute infection since IgG antibodies to Toxoplasma gondii are prevalent, and IgM antibodies can persist for months. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/38/16999?source=see_link\">",
"     \"Toxoplasmosis in immunocompetent hosts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Tularemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;FUO resulting from tularemia is more common with the pneumonic or typhoidal forms of the infection than with the glandular forms. The organism can be carried by a variety of animals and insects (ticks, mosquitoes, lice, fleas, flies), and can be acquired by a bite, ingestion, or inhalation (",
"    <a class=\"graphic graphic_table graphicRef71081 \" href=\"mobipreview.htm?7/37/7774\">",
"     table 2",
"    </a>",
"    ). Tularemia should be considered in children with a history of contact with animals, exposure to dead wild carcasses (eg, rabbits) or ingestion of rabbit or squirrel meat. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/10/30888?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of tularemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Viral infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most viruses cause self-limited infections of brief duration. However, cytomegalovirus (CMV), Epstein-Barr virus (EBV), adenovirus, hepatitis viruses, enteroviruses, and certain arboviruses can cause FUO. Symptoms and signs of these infections can be nonspecific and variable. Liver enzymes may be elevated. Viral cultures, serologic studies, and molecular techniques such as polymerase chain reaction (PCR) can be used to facilitate the diagnosis. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     LOCALIZED INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When common localized infections cause fever of unknown origin (FUO), they may have an unusual presentation. Careful and repeated history and physical examination, and careful review and interpretation of laboratory tests, can help to diagnose these infections. All findings, even those that may seem trivial, must be taken seriously. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/30/9706?source=see_link&amp;anchor=H4#H4\">",
"     \"Approach to the child with fever of unknown origin\", section on 'Diagnostic approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Bone and joint",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections involving the bones and joints usually present with recognizable symptoms. However, occasionally FUO can be the only manifestation, especially in young children who cannot vocalize their symptoms. This occurs more commonly with osteomyelitis than with septic arthritis. When FUO is the presenting complaint, the pelvic bones, small bones, and flat bones are more frequently involved than long bones.",
"   </p>",
"   <p>",
"    The diagnosis of osteomyelitis or septic arthritis can be suggested by imaging studies, including computed tomography (CT), magnetic resonance (MR) imaging, and radioisotopic bone scanning. All of these modalities are more sensitive than plain bone radiography. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/32/33289?source=see_link&amp;anchor=H6#H6\">",
"     \"Evaluation and diagnosis of hematogenous osteomyelitis in children\", section on 'Imaging'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/30/14826?source=see_link&amp;anchor=H16#H16\">",
"     \"Bacterial arthritis: Clinical features and diagnosis in infants and children\", section on 'Radiologic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Infective endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infective endocarditis (IE) is an infrequent but important cause of FUO in children. IE is rare in normal, term infants but increases in frequency as children age and usually occurs in the setting of a preexisting cardiac lesion. Acute bacterial endocarditis generally is fulminant in onset, whereas subacute infection is more indolent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/15/27896?source=see_link\">",
"     \"Infective endocarditis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of IE can be difficult to establish since patients do not always have positive blood cultures or a cardiac murmur, especially if the infection is confined to the right side of the heart. Associated nonspecific laboratory findings can include anemia, leukocytosis, and an elevated erythrocyte sedimentation rate (ESR).",
"   </p>",
"   <p>",
"    Viridans streptococci, enterococci, and staphylococci (including",
"    <em>",
"     S. aureus",
"    </em>",
"    and coagulase-negative staphylococci) are the organisms most commonly isolated. Blood cultures may be negative if patients have received a trial of empirical antibiotics, have right-sided cardiac involvement, or have infection caused by unusual or fastidious organisms (eg,",
"    <em>",
"     Brucella",
"    </em>",
"    ,",
"    <em>",
"     Coxiella burnetii",
"    </em>",
"    ,",
"    <em>",
"     Bartonella",
"    </em>",
"    spp., anaerobes, fungi).",
"   </p>",
"   <p>",
"    Children with suspected IE as the cause of FUO should have several blood cultures (aerobic and anaerobic) drawn over a 24-hour period before initiation of antimicrobial therapy. Echocardiography is frequently performed to assess damage to the heart valves and look for valvular vegetations. However, the absence of these findings does not exclude the diagnosis of IE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Intraabdominal abscess",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraabdominal abscesses, including liver, subphrenic, perinephric, and pelvic abscesses, can cause FUO. Patients may not have abdominal complaints at presentation. However, the index of suspicion for an abscess should increase if the patient has a history of prior intraabdominal disease, abdominal surgery, or vague abdominal pain.",
"   </p>",
"   <p>",
"    Pyogenic liver abscesses typically occur in immunocompromised children, but can arise in an immunocompetent child [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38905/abstract/21\">",
"     21",
"    </a>",
"    ]. Many children with liver abscess have hepatomegaly and right upper quadrant tenderness, but some only have fever. Liver enzymes are usually normal in these patients, and detectable bacteremia is uncommon.",
"   </p>",
"   <p>",
"    Depending upon the source of the abscess, common pathogens include",
"    <em>",
"     S. aureus",
"    </em>",
"    , streptococci,",
"    <em>",
"     Escherichia coli",
"    </em>",
"    , and anaerobes. Imaging of the abdomen, typically with ultrasonography or CT, generally demonstrates the collection. If imaging is negative, but clinical suspicion of intraabdominal abscess in high, radioisotope or gallium scanning may be warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Hepatic infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulomatous hepatitis, which can be caused by a number of organisms, is another cause of FUO in children. It occurs more commonly in adults, but cases have been reported in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38905/abstract/22\">",
"     22",
"    </a>",
"    ], especially in association with",
"    <em>",
"     Bartonella",
"    </em>",
"    . The diagnosis of granulomatous hepatitis can be suggested by ultrasonography or other diagnostic imaging. However, confirmation requires a biopsy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40406?source=see_link\">",
"     \"Hepatic granulomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bacterial cholangitis can occasionally cause FUO in the absence of jaundice and other liver function abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38905/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24790?source=see_link\">",
"     \"Acute cholangitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Upper respiratory tract infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is surprising how frequently upper respiratory tract infections (URI) and infections of related organs, such as mastoids or sinuses, present as FUO in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38905/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Mastoiditis, sinusitis, chronic or recurrent otitis media, chronic or recurrent pharyngitis, tonsillitis, peritonsillar abscess, and nonspecific URI have been reported as causes of FUO in children. One would expect these infections to be associated with localized symptoms, but it appears that complaints may be ignored as trivial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Urinary tract infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary tract infection is among the most common causes of FUO in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38905/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. In one series, the two most frequent laboratory errors were failure to perform a urinalysis and failure to adequately pursue the finding of pyuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38905/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21129?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features and diagnosis of urinary tract infections in infants and children older than one month\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     CONNECTIVE TISSUE DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Connective tissue disease is the second most common etiologic category of fever of unknown origin (FUO) in children. A positive antinuclear antibody test can suggest the presence of an underlying connective tissue disorder, particularly systemic lupus erythematosus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38905/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28520?source=see_link&amp;anchor=H2#H2\">",
"     \"Measurement and clinical significance of antinuclear antibodies\", section on 'Diseases associated with a positive ANA'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Juvenile idiopathic arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Juvenile idiopathic arthritis (JIA, formerly juvenile rheumatoid arthritis, JRA) is a chronic inflammatory disorder with three distinct forms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A systemic presentation with high, spiking fevers, evanescent rash, and lymphadenopathy",
"     </li>",
"     <li>",
"      Polyarticular involvement",
"     </li>",
"     <li>",
"      Monoarticular involvement, the so-called pauciarticular form",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fever can be observed with all of the three presentations but is nearly universal in the systemic form, which is the type of JIA most likely to present as FUO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38905/abstract/26\">",
"     26",
"    </a>",
"    ]. Arthritis may follow the development of fevers by months to years. Serologic tests are usually negative, and thus, JIA initially may be a diagnosis of exclusion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/35/21046?source=see_link\">",
"     \"Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/25/24983?source=see_link\">",
"     \"Polyarticular onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/31/24056?source=see_link\">",
"     \"Pauciarticular onset juvenile idiopathic arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other collagen connective tissue diseases to consider in the evaluation of FUO include polyarteritis nodosa and systemic lupus erythematosus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10810?source=see_link\">",
"     \"Systemic lupus erythematosus in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/26/9641?source=see_link\">",
"     \"Clinical manifestations and diagnosis of polyarteritis nodosa\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     NEOPLASMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukemia and lymphoma are the most common malignancies that cause fever of unknown origin (FUO) in children. Other, less common tumors include neuroblastoma, hepatoma, sarcoma, and atrial myxoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/58/4009?source=see_link\">",
"     \"Overview of the presentation and classification of acute lymphoblastic leukemia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/6/32874?source=see_link\">",
"     \"Overview of Hodgkin lymphoma in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/15/15609?source=see_link\">",
"     \"Clinical presentation, diagnosis, and staging evaluation of neuroblastoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/47/5882?source=see_link\">",
"     \"Clinical assessment of the child with suspected cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     OTHER CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The other noninfectious causes of fever of unknown origin (FUO) are varied, but can be summarized by the categories and examples below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     CNS dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with severe brain damage or other central nervous system (CNS) dysfunction can have altered thermoregulation and present with intermittent or recurrent elevated body temperatures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38905/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. One case was reported of an adolescent with episodes of fever who responded to",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    therapy, suggesting that a form of epilepsy was responsible for the fevers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38905/abstract/29\">",
"     29",
"    </a>",
"    ]. Epilepsy-induced fever also has been described in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38905/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. In another report, an adolescent had cyclic episodes of fever accompanied by nausea, vomiting, and emotional disturbance, resulting from a CNS lesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38905/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Diabetes insipidus",
"    </span>",
"    &nbsp;&mdash;&nbsp;FUO in infants and young children can be due to either central or nephrogenic diabetes insipidus (DI). Since polyuria and polydipsia can be difficult to appreciate during infancy, dehydration or hypernatremia may be unrecognized until hyperthermia, weight loss, and peripheral vascular collapse ensue. The diagnosis of DI can be established by evaluating electrolytes and osmolality simultaneously in serum and urine for periods of normal hydration and careful water deprivation. Serum levels of antidiuretic hormone (ADH) can also be determined by radioimmunoassay. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24312?source=see_link\">",
"     \"Diagnosis of polyuria and diabetes insipidus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Drug fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever is a common allergic reaction to drugs, and virtually any drug can cause a drug fever. When taking a medication history, it is important to include prescription, over-the-counter, and illicit drugs, as well as complementary and alternative therapies. Topical preparations, such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?25/13/25816?source=see_link\">",
"     atropine",
"    </a>",
"    , can also cause fever. The duration of use does not help in determining whether the agent is responsible for the FUO.",
"   </p>",
"   <p>",
"    In addition, some drugs impair thermoregulation or thermoregulatory control mechanisms and cause fever on this basis rather than as an allergic phenomenon. Examples include: phenothiazines, anticholinergic drugs, and epinephrine and related compounds.",
"   </p>",
"   <p>",
"    Neither the height of the fevers nor their pattern is helpful in judging whether drugs are the cause. Drugs can cause low grade or high and spiking fevers; the pattern can be continuous or intermittent. Fevers resulting from medications typically disappear within 48 to 72 hours of discontinuation of the drug, but can take as long as five to seven days to resolve and, occasionally, fever can persist for weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Factitious fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factitious fever, whether a false report by a parent or patient or related to manipulation of body temperature by rinsing the mouth with or dipping the thermometer bulb into hot liquid, can be difficult to establish as the etiology of FUO. However, a number of clues should raise the possibility of factitious fever. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Absence of tachycardia and nonspecific symptoms, such as malaise or discomfort, in a patient with a high fever",
"     </li>",
"     <li>",
"      Rapid defervescence without diaphoresis",
"     </li>",
"     <li>",
"      Failure of the temperature curve to show normal diurnal variation (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/8/18570?source=see_link&amp;anchor=H2#H2\">",
"       \"Pathophysiology and management of fever in infants and children\", section on 'Normal body temperature'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Extreme hyperpyrexia",
"     </li>",
"     <li>",
"      Discrepancies between temperatures recorded by the patient or by providers not in attendance and those obtained rectally or when someone is observing in the room",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Measuring the temperature of a freshly voided urine specimen, which reflects core body temperature, is one way to verify or exclude the presence of fever. The temperature of freshly voided urine closely parallels the temperature obtained orally. Electronic or one-time use thermometers that measure temperature rapidly reduce the likelihood that a recorded fever is factitious since a provider is usually in attendance to make these measurements.",
"   </p>",
"   <p>",
"    A more unusual cause of factitious fever is Munchausen syndrome or Munchausen syndrome by proxy in which one person, usually a parent, fabricates symptoms and signs of illness on behalf of the child. In some of these cases, fevers are actually induced by the injection of infective or foreign materials, either by the usually older patient or by a parent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/16/36104?source=see_link\">",
"     \"Munchausen syndrome by proxy (medical child abuse)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/21/7512?source=see_link\">",
"     \"Factitious disorder and Munchausen syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Familial dysautonomia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial dysautonomia (also called the Riley-Day syndrome and hereditary sensory autonomic neuropathy type 3 (HSAN3)), is an autosomal recessive disorder in which autonomic and peripheral sensory nerve dysfunction results in defective temperature regulation. Hyperthermia or hypothermia may be observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38905/abstract/35\">",
"     35",
"    </a>",
"    ]. The majority of affected children are of Ashkenazi Jewish parentage.",
"   </p>",
"   <p>",
"    A number of features in the history and physical examination can suggest familial dysautonomia, including a history of recurrent aspiration or vomiting because of poor coordination of swallowing, excessive salivation, diminished tearing, excessive or diminished sweating, labile blood pressure, and erythema or blanching of the skin. Fungiform papillae of the tongue may be sparse or absent, and the sense of taste is diminished [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38905/abstract/36\">",
"     36",
"    </a>",
"    ]. Absence of peripheral pain sensation can lead to multiple sites of skin trauma. Deep-tendon reflexes and corneal reflexes usually are impaired, and dysarthria is common. Patients with this syndrome also demonstrate mental deficiencies and emotional lability. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/16/43272?source=see_link&amp;anchor=H7#H7\">",
"     \"Hereditary sensory and autonomic neuropathies\", section on 'HSAN3 (Familial dysautonomia)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Hemophagocytic lymphohistiocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemophagocytic lymphohistiocytosis (HLH) is a non-malignant but life-threatening disorder in which uncontrolled proliferation of activated lymphocytes and histiocytes leads to hemophagocytosis and dysregulation and hypersecretion of inflammatory cytokines. HLH encompasses both familial and reactive disease triggered by infection, immunologic disorder, malignancy, or drugs. Typical manifestations of HLH are prolonged fever, hepatosplenomegaly, hyperferritinemia, and cytopenias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38905/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Other common findings include liver dysfunction, coagulopathy, hypertriglyceridemia or hypofibrinogenemia. Clinical presentations of patients with primary (familial) and secondary (reactive) HLH are indistinguishable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38905/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of HLH is based on a patient fulfilling at least five of eight criteria (fever, splenomegaly, bicytopenia, hypertriglyceridemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypofibrinogenemia, hemophagocytosis,",
"    <span class=\"nowrap\">",
"     low/absent",
"    </span>",
"    NK-cell-activity, hyperferritinemia, and high-soluble interleukin-2-receptor levels) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38905/abstract/41\">",
"     41",
"    </a>",
"    ]. HLH can manifest initially as FUO but can rapidly progress to resemble overwhelming sepsis and result in death; therefore, a high index of suspicion is required to establish the diagnosis. Therapy includes treating the underlying infection or trigger, if possible, and aggressive immune modulation therapies. Even with prompt and appropriate chemotherapy, mortality due to HLH is high [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38905/abstract/38,41,42\">",
"     38,41,42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/5/41050?source=see_link\">",
"     \"Hemophagocytic lymphohistiocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Immunodeficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;FUO also can be caused by a number of congenital and acquired immunodeficiency states (eg, HIV). Some children with immunoglobulin deficiencies (eg, Bruton agammaglobulinemia) have a history of recurrent fevers with or without focal infections. Others with lymphocyte function abnormalities are more likely to have persistent viral or parasitic infections in association with prolonged fevers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/48/24326?source=see_link\">",
"     \"Primary humoral immune deficiencies: An overview\"",
"    </a>",
"    .) (See appropriate topic reviews.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Infantile cortical hyperostosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infantile cortical hyperostosis (Caffey disease) is an inherited disease characterized by persistent fevers, sometimes as high as 40&ordm;C (104&ordm;F), subperiosteal bone hyperplasia, and swelling of overlying tissues. Patients with this disease can exhibit irritability and tenderness over the affected regions in addition to fever. Leukocytosis and an elevated ESR are common laboratory findings. These clinical features, in conjunction with radiologic demonstration of periosteal involvement, establish the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/23/11641?source=see_link&amp;anchor=H14#H14\">",
"     \"Differential diagnosis of the orthopedic manifestations of child abuse\", section on 'Infantile cortical hyperostosis (Caffey disease)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Inflammatory bowel disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever is a prominent component of inflammatory bowel disease (IBD) in many children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38905/abstract/43-45\">",
"     43-45",
"    </a>",
"    ] and may be more common than abdominal symptoms, especially in children with Crohn's disease. Ulcerative colitis is a less common cause of FUO in children than Crohn's disease; patients with ulcerative colitis typically have accompanying GI symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/7/24693?source=see_link\">",
"     \"Clinical manifestations of Crohn's disease in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/34/4650?source=see_link\">",
"     \"Treatment of ulcerative colitis in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Abdominal CT can be suggestive of IBD in children with prolonged FUO, even in the absence of GI symptoms, but contrast studies of the bowel with special attention to the terminal ileum should be performed, especially in patients with an elevated ESR accompanied by anemia, weight loss, failure of linear growth, or occult blood in the stool. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/25/27034?source=see_link\">",
"     \"Clinical features and diagnosis of inflammatory bowel disease in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Kawasaki disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kawasaki disease is a multisystem vasculitis of unknown, but possible infectious, etiology. It is an important cause of prolonged fever in childhood. The diagnosis is established primarily on the basis of the clinical findings (",
"    <a class=\"graphic graphic_table graphicRef67711 \" href=\"mobipreview.htm?3/48/3851\">",
"     table 3",
"    </a>",
"    ): bulbar conjunctivitis (",
"    <a class=\"graphic graphic_picture graphicRef78898 \" href=\"mobipreview.htm?15/1/15376\">",
"     picture 1",
"    </a>",
"    ), oral changes (",
"    <a class=\"graphic graphic_picture graphicRef68321 \" href=\"mobipreview.htm?0/2/43\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef59319 \" href=\"mobipreview.htm?19/34/20004\">",
"     picture 3",
"    </a>",
"    ), rash, changes in the hands and feet (",
"    <a class=\"graphic graphic_picture graphicRef72040 \" href=\"mobipreview.htm?25/12/25793\">",
"     picture 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef53452 \" href=\"mobipreview.htm?5/29/5587\">",
"     picture 5",
"    </a>",
"    ), and cervical adenopathy. These manifestations may not appear until the second week of fever or may have occurred and resolved by the time the patient is examined. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12248?source=see_link\">",
"     \"Kawasaki disease: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Periodic fevers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several different periodic fever disorders have been described. Some have been classified as autoinflammatory, referring to episodes of \"unprovoked\" inflammatory events, and are often, but not always, accompanied by fever. At least eight such hereditary disorders have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38905/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/8/15494?source=see_link\">",
"     \"Periodic fever syndromes and other autoinflammatory diseases: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The two most common heritable periodic fever disorders in children are familial Mediterranean fever (FMF) and hyperimmunoglobulin D syndrome (hyper-IgD syndrome or HIDS). The febrile episodes in these disorders usually recur at irregular intervals. Specific defective genes have been identified for both FMF and HIDS.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      FMF is an autosomal recessive disease found in individuals of Mediterranean descent. It is characterized by episodic fever and serosal inflammation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/63/38905/abstract/48\">",
"       48",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/31/25078?source=see_link\">",
"       \"Clinical manifestations and diagnosis of familial Mediterranean fever\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/32/32261?source=see_link\">",
"       \"Pathophysiology of familial Mediterranean fever\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      HIDS is also an autosomal recessive disease. Clinical manifestations include episodes of fever, skin eruptions, abdominal complaints, and joint involvement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/63/38905/abstract/49-51\">",
"       49-51",
"      </a>",
"      ]. The elevated serum IgD is probably a secondary effect, and some patients also have had elevated serum levels of IgA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/63/38905/abstract/52\">",
"       52",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/43/3768?source=see_link\">",
"       \"Hyperimmunoglobulin-D syndrome: Clinical manifestations and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cyclic neutropenia, also known as cyclic hematopoiesis, is another heritable cause of recurrent fevers. Children with this disorder are prone to fever during periods of severe neutropenia. Neutropenic cycles usually occur at regular intervals of 15 to 35 days, with 21 days being the most frequent pattern [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38905/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/61/42966?source=see_link\">",
"     \"Cyclic neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/40/40578?source=see_link\">",
"       \"Patient information: Fever in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/23/37235?source=see_link\">",
"       \"Patient information: Fever in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fever of unknown origin (FUO) has a number of infectious and noninfectious causes (",
"      <a class=\"graphic graphic_table graphicRef69379 \" href=\"mobipreview.htm?41/32/42509\">",
"       table 1",
"      </a>",
"      ). FUO is usually caused by common disorders, often with an unusual presentation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The three most common etiological categories of FUO in children in order of frequency are infectious diseases, connective tissue diseases, and neoplasms. In many cases, a definitive diagnosis is never established and fever resolves. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Generalized infections that cause FUO typically have nonspecific presenting features. Obtaining a detailed history of exposures can be critical to making the diagnosis of these disorders. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/30/9706?source=see_link&amp;anchor=H9#H9\">",
"       \"Approach to the child with fever of unknown origin\", section on 'Exposures'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H4\">",
"       'Generalized infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When common localized infections cause FUO, they may have an unusual presentation. Careful and repeated history and physical examination, and careful review and interpretation of laboratory tests, can help to diagnose these infections. All findings, even those that may seem trivial, must be taken seriously. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Localized infections'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/30/9706?source=see_link&amp;anchor=H4#H4\">",
"       \"Approach to the child with fever of unknown origin\", section on 'Diagnostic approach'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Noninfectious causes of FUO include collagen vascular diseases (eg, juvenile rheumatoid arthritis), neoplasms, central nervous system dysfunction, diabetes insipidus, Kawasaki disease, drug fever, factitious fever, inflammatory bowel disease, infantile cortical hyperostosis, and periodic fevers. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Other causes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/1\">",
"      Finkelstein JA, Christiansen CL, Platt R. Fever in pediatric primary care: occurrence, management, and outcomes. Pediatrics 2000; 105:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/2\">",
"      PETERSDORF RG, BEESON PB. Fever of unexplained origin: report on 100 cases. Medicine (Baltimore) 1961; 40:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/3\">",
"      Lohr JA, Hendley JO. Prolonged fever of unknown origin: a record of experiences with 54 childhood patients. Clin Pediatr (Phila) 1977; 16:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/4\">",
"      McClung HJ. Prolonged fever of unknown origin in children. Am J Dis Child 1972; 124:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/5\">",
"      Pizzo PA, Lovejoy FH Jr, Smith DH. Prolonged fever in children: review of 100 cases. Pediatrics 1975; 55:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/6\">",
"      Feigin RD, Shearer WT. Fever of unknown origin in children. Curr Probl Pediatr 1976; 6:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/7\">",
"      Cogulu O, Koturoglu G, Kurugol Z, et al. Evaluation of 80 children with prolonged fever. Pediatr Int 2003; 45:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/8\">",
"      Pasic S, Minic A, Djuric P, et al. Fever of unknown origin in 185 paediatric patients: a single-centre experience. Acta Paediatr 2006; 95:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/9\">",
"      Bourrillon A. [Management of prolonged fever in infants]. Arch Pediatr 1999; 6:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/10\">",
"      Jacobs RF, Schutze GE. Bartonella henselae as a cause of prolonged fever and fever of unknown origin in children. Clin Infect Dis 1998; 26:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/11\">",
"      Chantada G, Casak S, Plata JD, et al. Children with fever of unknown origin in Argentina: an analysis of 113 cases. Pediatr Infect Dis J 1994; 13:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/12\">",
"      Akpede GO, Akenzua GI. Management of children with prolonged fever of unknown origin and difficulties in the management of fever of unknown origin in children in developing countries. Paediatr Drugs 2001; 3:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/13\">",
"      Schneider T, Loddenkemper C, Rudwaleit M, et al. [Fever of unknown origin in the 21st century: infectious diseases]. Dtsch Med Wochenschr 2005; 130:2708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/14\">",
"      Arisoy ES, Correa AG, Wagner ML, Kaplan SL. Hepatosplenic cat-scratch disease in children: selected clinical features and treatment. Clin Infect Dis 1999; 28:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/15\">",
"      Van CT, Thuy NT, San NH, et al. Human leptospirosis in the Mekong delta, Viet Nam. Trans R Soc Trop Med Hyg 1998; 92:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/16\">",
"      Jackson LA, Kaufmann AF, Adams WG, et al. Outbreak of leptospirosis associated with swimming. Pediatr Infect Dis J 1993; 12:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/17\">",
"      Filler S, Causer LM, Newman RD, et al. Malaria surveillance--United States, 2001. MMWR Surveill Summ 2003; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/18\">",
"      Centers for Disease Control and Prevention (CDC). Local transmission of Plasmodium vivax malaria--Palm Beach County, Florida, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/19\">",
"      Tuberculin negative tuberculosis. Am Rev Respir Dis 1973; 107:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/20\">",
"      Steiner P, Portugaleza C. Tuberculous meningitis in children. A review of 25 cases observed between the years 1965 and 1970 at the Kings County Medical Center of Brooklyn with special reference to the problem of infection with primary drug-resistant strains of M. tuberculosis. Am Rev Respir Dis 1973; 107:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/21\">",
"      Kaplan SL, Feigin RD. Experience and reason--briefly recorded. Pediatrics 1976; 58:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/22\">",
"      Simon HB, Wolff SM. Granulomatous hepatitis and prolonged fever of unknown origin: a study of 13 patients. Medicine (Baltimore) 1973; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/23\">",
"      Weinstein L. Bacterial hepatitis: a case report on an unrecognized cause of fever of unknown origin. N Engl J Med 1978; 299:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/24\">",
"      Wyllie R, Fitzgerald JF. Bacterial cholangitis in a 10-week-old infant with fever of undetermined origin. Pediatrics 1980; 65:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/25\">",
"      Steele RW, Jones SM, Lowe BA, Glasier CM. Usefulness of scanning procedures for diagnosis of fever of unknown origin in children. J Pediatr 1991; 119:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/26\">",
"      Calabro JJ, Marchesano JM. Juvenile rheumatoid arthritis. N Engl J Med 1967; 277:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/27\">",
"      Lin KL, Wang HS. Reverse Shapiro's syndrome--an unusual cause of fever of unknown origin. Brain Dev 2005; 27:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/28\">",
"      Hirayama K, Hoshino Y, Kumashiro H, Yamamoto T. Reverse Shapiro's syndrome. A case of agenesis of corpus callosum associated with periodic hyperthermia. Arch Neurol 1994; 51:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/29\">",
"      Berger H. Fever. An unusual manifestation of epilepsy. Postgrad Med 1966; 40:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/30\">",
"      Matsuda N, Akanuma J, Shimizu S, et al. [Recurrent episodes of fever of unknown origin as temporal lobe epilepsy]. Rinsho Shinkeigaku 2000; 40:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/31\">",
"      Chan KM. Epilepsy--another cause of intermittent fever with confusion. Postgrad Med J 1992; 68:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/32\">",
"      el-Ad B, Neufeld MY. Periodic febrile confusion as a presentation of complex partial status epilepticus. Acta Neurol Scand 1990; 82:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/33\">",
"      Semel JD. Complex partial status epilepticus presenting as fever of unknown origin. Arch Intern Med 1987; 147:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/34\">",
"      WOLFF SM, ADLER RC, BUSKIRK ER, THOMPSON RH. A SYNDROME OF PERIODIC HYPOTHALAMIC DISCHARGE. Am J Med 1964; 36:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/35\">",
"      Dancis J, Smith AA. Familial dysautonomia. N Engl J Med 1966; 274:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/36\">",
"      SMITH AA, FARBMAN A, DANCIS J. TONGUE IN FAMILIAL DYSAUTONOMIA, A DIAGNOSTIC SIGN. Am J Dis Child 1965; 110:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/37\">",
"      Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Eur J Pediatr 2007; 166:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/38\">",
"      Palazzi DL, McClain KL, Kaplan SL. Hemophagocytic syndrome in children: an important diagnostic consideration in fever of unknown origin. Clin Infect Dis 2003; 36:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/39\">",
"      Aric&ograve; M, Janka G, Fischer A, et al. Hemophagocytic lymphohistiocytosis. Report of 122 children from the International Registry. FHL Study Group of the Histiocyte Society. Leukemia 1996; 10:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/40\">",
"      Henter JI, Elinder G, S&ouml;der O, Ost A. Incidence in Sweden and clinical features of familial hemophagocytic lymphohistiocytosis. Acta Paediatr Scand 1991; 80:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/41\">",
"      Henter JI, Horne A, Aric&oacute; M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007; 48:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/42\">",
"      Jordan MB, Allen CE, Weitzman S, et al. How I treat hemophagocytic lymphohistiocytosis. Blood 2011; 118:4041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/43\">",
"      CROHN BB, YARNIS H. Continuous fever of intestinal origin. Ann Intern Med 1947; 26:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/44\">",
"      LEE FI, DAVIES DM. Crohn's disease presenting as pyrexia of unknown origin. Lancet 1961; 1:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/45\">",
"      WALKER SH. Periodic fever in juvenile regional enteritis. J Pediatr 1962; 60:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/46\">",
"      Tunca M, Ozdogan H. Molecular and genetic characteristics of hereditary autoinflammatory diseases. Curr Drug Targets Inflamm Allergy 2005; 4:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/47\">",
"      Hayem F. [Periodic fevers]. Arch Pediatr 2002; 9:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/48\">",
"      SHAPIRO TR, EHRENFELD EN. Recurrent polyserositis (\"periodic disease,\" \"familial Mediterranean fever\") in children. Pediatrics 1962; 30:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/49\">",
"      Drenth JP, Haagsma CJ, van der Meer JW. Hyperimmunoglobulinemia D and periodic fever syndrome. The clinical spectrum in a series of 50 patients. International Hyper-IgD Study Group. Medicine (Baltimore) 1994; 73:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/50\">",
"      Grose C, Schnetzer JR, Ferrante A, Vladutiu AO. Children with hyperimmunoglobulinemia D and periodic fever syndrome. Pediatr Infect Dis J 1996; 15:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/51\">",
"      Grose C. Periodic fever in children with hyperimmunoglobulinemia D and mevalonate kinase mutations. Pediatr Infect Dis J 2005; 24:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/52\">",
"      Klasen IS, G&ouml;ertz JH, van de Wiel GA, et al. Hyper-immunoglobulin A in the hyperimmunoglobulinemia D syndrome. Clin Diagn Lab Immunol 2001; 8:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38905/abstract/53\">",
"      REIMANN HA. Periodic disease; periodic fever, periodic abdominalgia, cyclic neutropenia, intermittent arthralgia, angioneurotic edema, anaphylactoid purpura and periodic paralysis. J Am Med Assoc 1949; 141:175.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5996 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-200.215.4.194-84581B2B62-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_63_38905=[""].join("\n");
var outline_f37_63_38905=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H38\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      GENERALIZED INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Brucellosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cat scratch disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Leptospirosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Malaria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Mycobacterial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Salmonellosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Toxoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Tularemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Viral infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      LOCALIZED INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Bone and joint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Intraabdominal abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Hepatic infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Upper respiratory tract infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Urinary tract infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      CONNECTIVE TISSUE DISEASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Juvenile idiopathic arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      NEOPLASMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      OTHER CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      CNS dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Drug fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Factitious fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Familial dysautonomia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Hemophagocytic lymphohistiocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Infantile cortical hyperostosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Periodic fevers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5996\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5996|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/1/15376\" title=\"picture 1\">",
"      Conjunctivitis in Kawasaki",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/2/43\" title=\"picture 2\">",
"      Strawberry tongue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/34/20004\" title=\"picture 3\">",
"      Cracked red lips seen in Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/12/25793\" title=\"picture 4\">",
"      Edema of hands in Kawasaki disease - acute phase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/29/5587\" title=\"picture 5\">",
"      Periungual desquamation in Kawasaki disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5996|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/32/42509\" title=\"table 1\">",
"      Causes of FUO in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/37/7774\" title=\"table 2\">",
"      Zoonoses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/48/3851\" title=\"table 3\">",
"      Dx criteria KD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24790?source=related_link\">",
"      Acute cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/30/9706?source=related_link\">",
"      Approach to the child with fever of unknown origin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/30/14826?source=related_link\">",
"      Bacterial arthritis: Clinical features and diagnosis in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/47/5882?source=related_link\">",
"      Clinical assessment of the child with suspected cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/25/27034?source=related_link\">",
"      Clinical features and diagnosis of inflammatory bowel disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21129?source=related_link\">",
"      Clinical features and diagnosis of urinary tract infections in infants and children older than one month",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/31/25078?source=related_link\">",
"      Clinical manifestations and diagnosis of familial Mediterranean fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/26/9641?source=related_link\">",
"      Clinical manifestations and diagnosis of polyarteritis nodosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/7/24693?source=related_link\">",
"      Clinical manifestations of Crohn's disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/26/5543?source=related_link\">",
"      Clinical manifestations of malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/43/16058?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of brucellosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/21/20826?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of extrapulmonary and miliary tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/10/30888?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of tularemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/15/15609?source=related_link\">",
"      Clinical presentation, diagnosis, and staging evaluation of neuroblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/61/42966?source=related_link\">",
"      Cyclic neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/0/10248?source=related_link\">",
"      Diagnosis of malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24312?source=related_link\">",
"      Diagnosis of polyuria and diabetes insipidus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/23/11641?source=related_link\">",
"      Differential diagnosis of the orthopedic manifestations of child abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/2/42024?source=related_link\">",
"      Epidemiology, microbiology, clinical manifestations, and diagnosis of typhoid fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/32/33289?source=related_link\">",
"      Evaluation and diagnosis of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/21/7512?source=related_link\">",
"      Factitious disorder and Munchausen syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/14/22762?source=related_link\">",
"      Fever without a source in children 3 to 36 months of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/5/41050?source=related_link\">",
"      Hemophagocytic lymphohistiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40406?source=related_link\">",
"      Hepatic granulomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/16/43272?source=related_link\">",
"      Hereditary sensory and autonomic neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/43/3768?source=related_link\">",
"      Hyperimmunoglobulin-D syndrome: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/15/27896?source=related_link\">",
"      Infective endocarditis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/61/12248?source=related_link\">",
"      Kawasaki disease: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/53/13143?source=related_link\">",
"      Latent tuberculosis infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28520?source=related_link\">",
"      Measurement and clinical significance of antinuclear antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/19/14649?source=related_link\">",
"      Microbiology and epidemiology of salmonellosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/61/33751?source=related_link\">",
"      Microbiology, epidemiology, and pathogenesis of Brucella",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/47/23289?source=related_link\">",
"      Microbiology, epidemiology, clinical manifestations, and diagnosis of cat scratch disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43879?source=related_link\">",
"      Microbiology, epidemiology, clinical manifestations, and diagnosis of leptospirosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/16/36104?source=related_link\">",
"      Munchausen syndrome by proxy (medical child abuse)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/55/38777?source=related_link\">",
"      Mycobacterium avium complex (MAC) infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/6/32874?source=related_link\">",
"      Overview of Hodgkin lymphoma in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/9/15512?source=related_link\">",
"      Overview of nontuberculous mycobacteria (excluding MAC) in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/11/24759?source=related_link\">",
"      Overview of nontuberculous mycobacterial infections in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/58/4009?source=related_link\">",
"      Overview of the presentation and classification of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/8/18570?source=related_link\">",
"      Pathophysiology and management of fever in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/32/32261?source=related_link\">",
"      Pathophysiology of familial Mediterranean fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?36/23/37235?source=related_link\">",
"      Patient information: Fever in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/40/40578?source=related_link\">",
"      Patient information: Fever in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/31/24056?source=related_link\">",
"      Pauciarticular onset juvenile idiopathic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/8/15494?source=related_link\">",
"      Periodic fever syndromes and other autoinflammatory diseases: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/25/24983?source=related_link\">",
"      Polyarticular onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/48/24326?source=related_link\">",
"      Primary humoral immune deficiencies: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10810?source=related_link\">",
"      Systemic lupus erythematosus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/35/21046?source=related_link\">",
"      Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/38/16999?source=related_link\">",
"      Toxoplasmosis in immunocompetent hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/31/4597?source=related_link\">",
"      Treatment and prevention of leptospirosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/34/4650?source=related_link\">",
"      Treatment of ulcerative colitis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/4/23625?source=related_link\">",
"      Tuberculosis disease in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_63_38906="Overview of the therapy of heart failure due to systolic dysfunction";
var content_f37_63_38906=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the therapy of heart failure due to systolic dysfunction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/63/38906/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/63/38906/contributors\">",
"     Wilson S Colucci, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/63/38906/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/63/38906/contributors\">",
"     Stephen S Gottlieb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/63/38906/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/63/38906/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/63/38906/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart failure (HF) is a common clinical syndrome representing the end-stage of a number of different cardiac diseases. It can result from any structural or functional cardiac disorder that impairs the ability of the ventricle to fill with or eject blood. There are two mechanisms by which reduced cardiac output and HF occur: systolic dysfunction and diastolic dysfunction.",
"   </p>",
"   <p>",
"    An overview of the management of HF due to systolic dysfunction, including the treatment of associated conditions, will be presented here [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Drugs that should be avoided or used with caution in patients with HF, the management of refractory HF, and therapy of HF due to diastolic dysfunction are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/3/42039?source=see_link\">",
"     \"Drugs that should be avoided or used with caution in patients with heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/40/4743?source=see_link\">",
"     \"Management of refractory heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7018?source=see_link\">",
"     \"Treatment and prognosis of diastolic heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Chronic versus acute decompensated HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following discussion will emphasize the therapeutic approach to the patient with chronic HF. The management of acute decompensated HF requiring hospitalization is presented separately. Such patients typically present with dyspnea and often have rales with or without peripheral edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/7/41079?source=see_link\">",
"     \"Treatment of acute decompensated heart failure: General considerations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33446?source=see_link\">",
"     \"Treatment of acute decompensated heart failure in acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Major society guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several major societies have published extensive guidelines for the treatment of HF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/1,3,5,6\">",
"     1,3,5,6",
"    </a>",
"    ]. These include the 2005 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines with 2009 focused update [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/1\">",
"     1",
"    </a>",
"    ], the 2006 Canadian Cardiovascular Society consensus conference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/5\">",
"     5",
"    </a>",
"    ], the 2008 European Society of Cardiology (ESC) guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/3\">",
"     3",
"    </a>",
"    ], and the 2010 Heart Failure Society of America guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With few exceptions, these societies make similar recommendations regarding the treatment of HF due to systolic dysfunction. Our approach is in broad agreement with these guidelines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20200800\">",
"    <span class=\"h2\">",
"     Goals of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of HF therapy are clinical improvement followed by stabilization and ultimately a reduction in risk of morbidity (including the rate of hospitalization) and mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20200745\">",
"    <span class=\"h2\">",
"     Components of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of HF begins with an accurate assessment of the etiology and severity of the disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19945?source=see_link\">",
"     \"Evaluation of the patient with suspected heart failure\"",
"    </a>",
"    .) This is followed by a therapeutic regimen aimed at the following factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Correction of systemic factors (eg, thyroid dysfunction, infection, uncontrolled diabetes) (",
"      <a class=\"graphic graphic_table graphicRef73383 \" href=\"mobipreview.htm?35/30/36331\">",
"       table 1",
"      </a>",
"      ), as well as comorbidities such as chronic obstructive pulmonary disease and sleep apnea. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/43/8888?source=see_link\">",
"       \"Cheyne-Stokes breathing and obstructive sleep apnea in heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lifestyle modification &mdash; There have been no randomized trials to document the benefits of lifestyle modification, all of which are based upon observational studies and physiologic rationale.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Cessation of smoking",
"     </li>",
"     <li>",
"      Restriction of alcohol consumption",
"     </li>",
"     <li>",
"      Salt restriction to approximately 2 to 3 g (or less) of sodium per day to minimize fluid accumulation. (See",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/61/39890?source=see_link\">",
"       \"Patient information: Low sodium diet (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Weight reduction in obese subjects with goal of being within 10 percent of ideal body weight",
"     </li>",
"     <li>",
"      Daily weight monitoring to detect fluid accumulation before it becomes symptomatic",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Review of drugs that may contribute to HF (eg, nonsteroidal antiinflammatory drugs, antiarrhythmic drugs, calcium channel blockers, thiazolidinediones). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/3/42039?source=see_link\">",
"       \"Drugs that should be avoided or used with caution in patients with heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pneumococcal vaccination and annual influenza vaccination [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/3,6\">",
"       3,6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21705?source=see_link\">",
"       \"Pneumococcal vaccination in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=see_link\">",
"       \"Seasonal influenza vaccination in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of the cause of the heart disease. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment of the underlying cardiovascular disease'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Pharmacologic therapy to relieve symptoms (including the risk of hospitalization), slow the progression of the HF, and improve patient survival. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Pharmacologic therapy of HF'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Two types of devices are recommended in selected patients with HF (",
"      <a class=\"graphic graphic_table graphicRef81590 \" href=\"mobipreview.htm?40/1/40989\">",
"       table 2",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      An implantable cardioverter-defibrillator (ICD) for secondary prevention of sudden cardiac death (SCD) and for primary prevention in selected patients. The criteria for ICD implantation are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/62/15338?source=see_link\">",
"       \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/55/19322?source=see_link\">",
"       \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiac resynchronization therapy (CRT) with biventricular pacing can improve symptoms and survival in selected patients who are in sinus rhythm and have a reduced left ventricular ejection fraction, and a prolonged QRS duration. Most patients who satisfy criteria for CRT implantation are also candidates for an ICD and receive a combined device. Criteria for CRT use are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/56/18314?source=see_link\">",
"       \"Cardiac resynchronization therapy in heart failure: Indications\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Specialized management for HF that is refractory to maximal oral pharmacologic therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/40/4743?source=see_link\">",
"       \"Management of refractory heart failure\"",
"      </a>",
"      .) Cardiac transplantation and mechanical circulatory support are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34297?source=see_link\">",
"       \"Indications and contraindications for cardiac transplantation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/57/37785?source=see_link\">",
"       \"Intermediate- and long-term mechanical cardiac support\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For hospitalized patients, comprehensive discharge support including close follow-up in the immediate postdischarge period may reduce the risk of rehospitalization. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/2/37929?source=see_link&amp;anchor=H14824299#H14824299\">",
"       \"Strategies to reduce hospitalizations in patients with heart failure\", section on 'Inpatient and transitional care strategies'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TREATMENT OF THE UNDERLYING CARDIOVASCULAR DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Underlying conditions that predispose to the development or exacerbation of HF should be identified and treated (",
"    <a class=\"graphic graphic_table graphicRef80859 \" href=\"mobipreview.htm?41/45/42716\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/8/15497?source=see_link&amp;anchor=H10#H10\">",
"     \"Epidemiology and causes of heart failure\", section on 'Predisposing conditions for HF'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/0/19465?source=see_link\">",
"     \"Causes of dilated cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is the primary cause of HF in many patients. In addition, hypertension imposes an increased hemodynamic load on the failing ventricle in patients with established HF. The goals of therapy are to reduce both preload (to diminish congestive symptoms) and afterload (to improve cardiac function).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Drug therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A beta blocker, an angiotensin converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB), and an aldosterone antagonist are the preferred antihypertensive agents because, as will be described below, they improve survival in patients with HF. Beta blockers can also provide anginal relief in patients with ischemic heart disease and rate control in those with atrial fibrillation. Beta blocker therapy should always be initiated at very low doses to minimize the risk of cardiac decompensation. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Initiation of therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For patients who are still hypertensive after initiation of beta blockers and ACE inhibitors",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ARBs, or who cannot tolerate these drugs, appropriate agents include loop diuretics, nitrates,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    , and some vasoselective calcium channel blockers (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/45/2775?source=see_link\">",
"     felodipine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/22/29031?source=see_link\">",
"     \"Treatment of hypertension in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Renovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another consideration in patients with HF and hypertension is renovascular disease, particularly in those with HF due to ischemic heart disease.",
"   </p>",
"   <p>",
"    Recurrent unexplained heart failure decompensation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    flash (sudden-onset) pulmonary edema occurs in some patients with renovascular hypertension, often with preserved (normal or near normal) left ventricular systolic function. Flash pulmonary edema appears to be more common in patients with bilateral renal artery stenosis as compared to those with unilateral disease (eg, 41 versus 12 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The combination of bilateral renal artery stenosis and flash pulmonary edema has been named the Pickering syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Acute treatment of acute decompensated heart failure (ADHF) in patients with this syndrome includes blood pressure control and, in some cases, diuresis. However, in patients who are euvolemic or dehydrated, diuresis should be avoided as it may lead to renal insufficiency, and preload reduction with nitrates is preferable.",
"   </p>",
"   <p>",
"    Only limited observational data are available on the efficacy of revascularization for this condition. A review of revascularization (percutaneous, largely with stenting, or surgery) in 87 reported cases of bilateral renal artery stenosis and flash pulmonary edema reported that renal function improved in 81 percent and 92 percent had no further episodes of flash pulmonary edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/10\">",
"     10",
"    </a>",
"    ]. However, these data must be viewed with caution given the limited controls and risk of bias in these case series.",
"   </p>",
"   <p>",
"    The 2005 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    peripheral arterial disease guidelines recommended percutaneous revascularization for patients with hemodynamically significant renal artery stenosis and recurrent, unexplained heart failure or sudden unexplained pulmonary edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/12\">",
"     12",
"    </a>",
"    ]. However, an AHA writing group later noted that treatment of atherosclerotic renal artery disease is controversial since the benefits and risks are not well-defined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/54/8040?source=see_link\">",
"     \"Treatment of bilateral atherosclerotic renal artery stenosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/43/29369?source=see_link\">",
"     \"Treatment of unilateral atherosclerotic renal artery stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Ischemic heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary atherosclerosis is the most common cause of cardiomyopathy in the United States, comprising 50 to 75 percent of patients with HF. In addition, coronary disease may be present in patients with HF of other causes, and may sometimes be overlooked as a contributing factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with ischemic heart disease may have HF from one or both of two mechanisms: a prior myocardial infarction (MI) followed by left ventricular dysfunction and remodeling; or hibernating myocardium due to chronic but potentially reversible ischemic dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. A separate issue is that patients with idiopathic dilated cardiomyopathy with a normal coronary arteriogram at diagnosis may over time develop significant coronary atherosclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All patients with documented ischemic heart disease should be treated medically for relief of angina and with risk factor reduction, such as rigorous control of serum lipids. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/28/3529?source=see_link\">",
"     \"Overview of the care of patients with stable ischemic heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Myocardial revascularization with angioplasty or bypass surgery may improve symptom status, exercise capacity, and prognosis in selected patients with dysfunctional yet viable (hibernating or stunned) myocardium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/41/10905?source=see_link\">",
"     \"Evaluation of hibernating myocardium\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/3/24633?source=see_link\">",
"     \"Diagnosis and management of ischemic cardiomyopathy\"",
"    </a>",
"    .) Revascularization should also be considered in patients with a history of repeated episodes of acute left ventricular dysfunction and flash pulmonary edema. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/23/7544?source=see_link\">",
"     \"Evaluation of acute decompensated heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Valvular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Valvular heart disease is the primary cause of HF in perhaps 10 to 12 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/2\">",
"     2",
"    </a>",
"    ] In addition, valvular dysfunction is a secondary or superimposed phenomenon in many cases of HF. As an example, some degree of mitral and tricuspid regurgitation is almost always present in patients with severe dilated cardiomyopathy, regardless of etiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/36/9799?source=see_link\">",
"     \"Functional mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Valvular disease imposes a hemodynamic load on the ventricles, leading to further impairment in cardiac function, regardless of whether the valvular disease is primary or secondary. Surgical correction of valvular disease, such as aortic or mitral stenosis or regurgitation or tricuspid regurgitation, can lead to improvement in cardiac function and resolution of symptoms. (See appropriate topics for the indications for surgery with various valvular lesions).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a variety of other potentially reversible conditions that can impair left ventricular function and cause, or worsen, HF. These include alcohol abuse, cocaine abuse, obstructive sleep apnea, nutritional deficiencies, myocarditis, hemochromatosis, sarcoidosis, thyroid disease, and rheumatologic disorders such as systemic lupus erythematosus. The evaluation to detect these conditions should include a careful history, including a history of systemic or other noncardiac disease, and, in some cases, consideration of endomyocardial biopsy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/0/19465?source=see_link\">",
"     \"Causes of dilated cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19945?source=see_link\">",
"     \"Evaluation of the patient with suspected heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/26/7592?source=see_link\">",
"     \"Endomyocardial biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC THERAPY OF HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of pharmacologic therapy are to improve symptoms (including risk of hospitalization), slow or reverse deterioration in myocardial function, and reduce mortality. While the initial goal is to alleviate symptoms, drug therapy should be titrated as tolerated to target ranges for optimum clinical benefit. The benefits observed from aggressive monitoring strategies (eg, brain natriuretic peptide guided therapy) (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19818?source=see_link&amp;anchor=H20#H20\">",
"     \"Natriuretic peptide measurement in heart failure\", section on 'Chronic HF'",
"    </a>",
"    ) suggest that treatment beyond clinical congestion may improve outcomes. Additional pharmacologic therapy is directed at the prevention of arrhythmias and embolic events and the treatment of anemia and other possible exacerbating factors (",
"    <a class=\"graphic graphic_table graphicRef73383 \" href=\"mobipreview.htm?35/30/36331\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The treatment of HF in pregnancy involves specific concern about the effects of medications on the fetus and the mother, and therefore is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/34/1577?source=see_link\">",
"     \"Management of heart failure in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of drugs are recommended in HF for symptom relief and improvement in outcome (",
"    <a class=\"graphic graphic_table graphicRef81590 \" href=\"mobipreview.htm?40/1/40989\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Improvement in symptoms can be achieved by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      , diuretics, beta blockers, angiotensin converting enzyme (ACE) inhibitors, and angiotensin II receptor blockers (ARBs).",
"     </li>",
"     <li>",
"      Prolongation of patient survival has been documented with diuretics, beta blockers, ACE inhibitors, beta blockers, ARBs,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      plus nitrate, and aldosterone antagonists.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A review of data from the PROVED and RADIANCE trials supported the use of combination therapy with an ACE inhibitor,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , and diuretics for initial management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/19\">",
"     19",
"    </a>",
"    ]. Subsequent studies showed that addition of beta blockers and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    provides further benefit (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H16\">",
"     'ACE inhibitors'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H19\">",
"     'Beta blockers'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H25\">",
"     'Aldosterone antagonists'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We recommend the following approach to the long-term management of patients with HF. This approach is generally in agreement with the 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    task force guidelines for the treatment of HF (",
"    <a class=\"graphic graphic_table graphicRef81590 \" href=\"mobipreview.htm?40/1/40989\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/1\">",
"     1",
"    </a>",
"    ]. The data supporting these summary recommendations are discussed in detail in the appropriate topic reviews. Although the use of evidence-based HF therapies has improved due in part to national efforts such as the American Heart Association &ldquo;Get With the Guidelines&rdquo; program, the underutilization of evidence-based HF therapies continues to contribute to substantial excessive mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Order of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend the following sequence of drugs in the typical patient, with allowance for variations depending upon clinical response:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Loop diuretics are introduced first for fluid control in patients in overt HF. The goal is relief of signs or symptoms of volume overload, such as dyspnea and peripheral edema. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Diuretics'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      ACE inhibitors, or if not tolerated, angiotensin II receptor blockers (ARBs) are typically initiated during or after the optimization of diuretic therapy. These drugs are usually started at low doses and then titrated to goals based upon trial data. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'ACE inhibitors'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Beta blockers are initiated after the patient is stable on ACE inhibitors, again beginning at low doses with titration to trial goals as tolerated. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Beta blockers'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following drugs should be given to selected patients in the absence of a contraindication:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The addition of an aldosterone antagonist (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      or, if not tolerated,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5031?source=see_link\">",
"       eplerenone",
"      </a>",
"      ) to improve survival in patients who can be monitored for preserved renal function and a normal plasma potassium concentration and have NYHA functional class II HF and a left ventricular ejection fraction (LVEF) &le;30 percent; or NYHA functional class III to IV HF and an LVEF &lt;35 percent (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"       table 4",
"      </a>",
"      ); or are post-ST elevation myocardial infarction and already receiving therapeutic doses of ACE inhibitor, have an LVEF &le;40 percent, and have either symptomatic heart failure or diabetes mellitus. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Aldosterone antagonists'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Angiotensin II receptor blockers (ARBs) as an alternative to ACE inhibitors in patients who cannot tolerate these drugs. (See",
"      <a class=\"local\" href=\"#H27822027\">",
"       'Angiotensin II receptor blockers'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The addition of the combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      and a nitrate for patients (particularly blacks) with a reduced LVEF who have persistent symptoms despite therapy with an ACE inhibitor and beta blocker. (See",
"      <a class=\"local\" href=\"#H27821874\">",
"       'Hydralazine plus nitrates'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"       Digoxin",
"      </a>",
"      to reduce hospitalization for HF or, for patients with concomitant atrial fibrillation, for rate control. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Digoxin'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     ACE inhibitors or beta blockers first",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of ACE inhibitors before beta blockers is largely based upon clinical trials with ACE inhibitors being performed before trials of beta blockers. Subsequent randomized trials (eg, CIBIS III) suggest that the outcomes may be similar if beta blockers are given first [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The approach we recommend is based upon the differences in time to benefit and the importance of attaining target dose between these two drug classes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ACE inhibitors provide rapid hemodynamic benefit and will not exacerbate heart failure in the short run [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16090?source=see_link&amp;anchor=H10#H10\">",
"       \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\", section on 'Effect of dose'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The hemodynamic benefits of beta blockers are delayed (and there may be a transient worsening in cardiac function when therapy is initiated), but the long-term improvements in left ventricular ejection fraction (LVEF) and survival are dose-dependent in patients who can tolerate the target dose (",
"      <a class=\"graphic graphic_figure graphicRef57443 \" href=\"mobipreview.htm?40/3/41021\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/24\">",
"       24",
"      </a>",
"      ]. However, patients who cannot tolerate the target dose may derive similar benefit as those who can, if they attain the same degree of beta blockade, as assessed from the reduction in heart rate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/25\">",
"       25",
"      </a>",
"      ]. These observations suggest that some patients have higher sensitivity to beta blockers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given these considerations, we start with a low dose of an ACE inhibitor (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    5",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    increase to a moderate dose (eg, lisinopril 15 to 20",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    at one to two week intervals, and then begin a beta blocker, gradually increasing toward the target dose or, if this cannot be achieved, the highest tolerated dose. When the beta blocker titration is completed, the ACE inhibitor titration is completed. In patients with low risk of adverse response to ACE inhibitors (good blood pressure, no hyponatremia, hyperkalemia or risk of intravascular depletion), higher doses of the ACE inhibitor can be started and the titration can be quicker.",
"   </p>",
"   <p>",
"    Complications that develop during dose titration should be treated. For example, the diuretic dose should be increased for fluid overload [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/1\">",
"     1",
"    </a>",
"    ]. Hypotension rarely limits",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    titration, but may occur with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    due to its additional vasodilator activity. If hypotension limits carvedilol titration, one should consider a change to metoprolol.",
"   </p>",
"   <p>",
"    Since many patients with HF have low blood pressures, we generally alter the regimen only for symptoms or signs of underperfusion. A cardiologist should be consulted for patients who have difficulty attaining target doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sodium and water retention lead to the common congestive symptoms of pulmonary and peripheral edema. Fluid overload can typically be controlled and symptoms improved by diuretic therapy. Improvement in symptoms can occur within hours to days. In comparison, the clinical effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , ACE inhibitors, and beta blockers may require weeks or months to become fully apparent.",
"   </p>",
"   <p>",
"    Although data on diuretic efficacy are limited, a meta-analysis of a few small trials found that diuretics were associated with reduction in mortality as well as reduced admission for worsening heart failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/55/3962?source=see_link&amp;anchor=H31397796#H31397796\">",
"     \"Use of diuretics in patients with heart failure\", section on 'Efficacy and safety'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As stated in the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association HF guidelines (last updated in 2009), the goal of diuretic therapy is to eliminate clinical evidence of fluid retention, such as elevated jugular venous pressure and peripheral edema [",
"    <a class=\"external\" href=\"file://www.uptodate.com/contents/use-of-diuretics-in-patients-with-heart-failure/abstract/1\">",
"     1",
"    </a>",
"    ]. This goal should be pursued while adverse effects are monitored (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/55/3962?source=see_link&amp;anchor=H4016559#H4016559\">",
"     \"Use of diuretics in patients with heart failure\", section on 'Goals of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Appropriate diuretic usage can also affect the success of other drugs given for the treatment of HF. Inappropriately low doses will result in fluid retention, which can diminish the response to ACE inhibitors and ARBs and increase the risk of decompensation with the use of beta blockers. Conversely, excessive diuresis will lead to volume contraction, which can increase the risk of hypotension and renal insufficiency with ACE inhibitors, ARBs, and beta blockers.",
"   </p>",
"   <p>",
"    The most commonly used loop diuretic for the treatment of HF is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    , but some patients respond better to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/9/43158?source=see_link\">",
"     bumetanide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/13/28886?source=see_link\">",
"     torsemide",
"    </a>",
"    because of superior and more predictable absorption. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/55/3962?source=see_link\">",
"     \"Use of diuretics in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The usual starting dose in outpatients with HF is 20 to 40 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    or its equivalent. Subsequent dosing is determined by the diuretic response. In patients who are volume overloaded, a reasonable goal is weight reduction of 1.0",
"    <span class=\"nowrap\">",
"     kg/day.",
"    </span>",
"    If a patient does not respond, the diuretic dose should initially be increased to find the single effective dose, rather than giving the same dose twice a day.",
"   </p>",
"   <p>",
"    Intravenous diuretics (either as a bolus or a continuous infusion) are more potent than their equivalent oral doses, and may be required for unstable or severe disease. Thiazide diuretics can be added for a synergistic effect. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/55/3962?source=see_link\">",
"     \"Use of diuretics in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The fall in intracardiac filling pressure that results from diuretic-induced fluid removal may lower the cardiac output via the Frank-Starling relationship. This effect is usually minor and does not interfere with therapy. However, an otherwise unexplained rise in BUN and serum creatinine should be viewed as a sign of a potentially important reduction in tissue perfusion. Further diuresis should be performed only with careful monitoring for signs and symptoms attributable to hypoperfusion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/55/3962?source=see_link\">",
"     \"Use of diuretics in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Over the long term, diuretic therapy should be maintained to prevent recurrent edema. In many cases, this adjustment can be facilitated by having the patient record his or her weight each day and allowing him or her to make changes in dose if the weight increases or decreases beyond a specified range.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     ACE inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACE inhibitors improve survival in patients with left ventricular systolic dysfunction (LVEF &le;40 percent), ranging from asymptomatic left ventricular dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/27\">",
"     27",
"    </a>",
"    ] to moderate or severe HF (",
"    <a class=\"graphic graphic_figure graphicRef75136 graphicRef70015 graphicRef62325 \" href=\"mobipreview.htm?20/46/21231\">",
"     figure 2A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. Although some concern has been raised concerning their effectiveness in blacks, the available evidence is",
"    <strong>",
"     not",
"    </strong>",
"    sufficient to support a difference in ACE inhibitor use based on race. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16090?source=see_link\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H29\">",
"     'Influence of race'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    All patients with asymptomatic or symptomatic left ventricular dysfunction should be started on an ACE inhibitor. Beginning therapy with low doses (eg, 2.5 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    twice daily, 6.25 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    three times daily, or 5 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    once daily) will reduce the likelihood of hypotension and azotemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/32\">",
"     32",
"    </a>",
"    ]. If initial therapy is tolerated, the dose is then gradually increased at one to two week intervals to, if tolerated, a target dose of 20 mg twice daily of enalapril, 50 mg three times daily of captopril, or up to 40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of lisinopril or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/29/24024?source=see_link\">",
"     quinapril",
"    </a>",
"    . Blood should be obtained in all patients one to two weeks after starting or changing a dose and periodically thereafter to assess the plasma potassium concentration and renal function.",
"   </p>",
"   <p>",
"    These relatively high doses are recommended because they were used in the successful trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/1\">",
"     1",
"    </a>",
"    ]. Although there is uncertainty if these doses are much more beneficial than lower doses, maximum dose therapy, if tolerated, is still recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/1,33,34\">",
"     1,33,34",
"    </a>",
"    ]. If the target doses cannot be administered or are poorly tolerated, lower doses should be used with the expectation that there are likely to be only small differences in efficacy between low and high doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/1,33\">",
"     1,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16090?source=see_link&amp;anchor=H10#H10\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\", section on 'Effect of dose'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Impact of aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some evidence suggests that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    inhibits the acute hemodynamic effects of ACE inhibitors. However, most of the evidence does not support an inhibitory effect of aspirin on the long-term outcome benefits of ACE inhibitors in HF. For patients with known coronary artery disease, ASA is still recommended. However, there is no evidence for using aspirin in patients without coronary artery disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16090?source=see_link&amp;anchor=H12#H12\">",
"     \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\", section on 'Use with aspirin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/3/42039?source=see_link&amp;anchor=H6#H6\">",
"     \"Drugs that should be avoided or used with caution in patients with heart failure\", section on 'Aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least certain beta blockers, particularly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    succinate, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/29/2520?source=see_link\">",
"     bisoprolol",
"    </a>",
"    , improve overall and event-free survival in patients with New York Heart Association (NYHA) class II to III HF (",
"    <a class=\"graphic graphic_table graphicRef68693 \" href=\"mobipreview.htm?15/22/15724\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/35-37\">",
"     35-37",
"    </a>",
"    ] and probably in class IV HF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Beta blockers with intrinsic sympathomimetic activity (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/15/10487?source=see_link\">",
"     pindolol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/11/37047?source=see_link\">",
"     acebutolol",
"    </a>",
"    ) should be",
"    <strong>",
"     avoided",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/27/36282?source=see_link\">",
"     \"Rationale for and clinical trials of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The beta blocker trials in HF were carried out in patients receiving therapy with an ACE inhibitor; thus, the improvement in survival is additive to that induced by ACE inhibitors (",
"    <a class=\"graphic graphic_figure graphicRef70054 \" href=\"mobipreview.htm?28/9/28829\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The magnitude of benefit was illustrated in a meta-analysis that included 22 trials involving more than 10,000 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/35\">",
"     35",
"    </a>",
"    ]. Compared to placebo, beta blockers significantly reduced mortality at one year (odds ratio 0.65) and two years (odds ratio 0.72). During the first year, it was estimated that beta blocker therapy saved 3.8 lives per 100 patients treated and was associated with four fewer hospitalizations per 100 patients treated.",
"   </p>",
"   <p>",
"    The controlled trials, which evaluated the role of beta blockers in HF, excluded patients with relative contraindications to beta blocker therapy. Relative contraindications in patients with HF include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Heart rate &lt;60 bpm",
"     </li>",
"     <li>",
"      Symptomatic hypotension",
"     </li>",
"     <li>",
"      Greater than minimal evidence of fluid retention",
"     </li>",
"     <li>",
"      Signs of peripheral hypoperfusion",
"     </li>",
"     <li>",
"      PR interval &gt;0.24 sec",
"     </li>",
"     <li>",
"      Second- or third-degree atrioventricular block",
"     </li>",
"     <li>",
"      History of asthma or reactive airways",
"     </li>",
"     <li>",
"      Peripheral artery disease with resting limb ischemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Choice of agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/29/2520?source=see_link\">",
"     bisoprolol",
"    </a>",
"    or extended release",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    succinate since these beta blockers have been shown to reduce all-cause mortality and decrease hospitalization in patients with HF and left ventricular systolic dysfunction (LVEF &le; 35 to 40 percent) in randomized controlled trials.",
"   </p>",
"   <p>",
"    Limited data are available on the comparative efficacy of these three beta blockers. Indirect evidence suggests that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    may produce greater improvement in LVEF than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    . Patients with low blood pressure may be less likely to tolerate carvedilol because of its vasodilatory activity. Conversely, carvedilol may be preferred in patients with higher blood pressure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/27/36282?source=see_link&amp;anchor=H18#H18\">",
"     \"Rationale for and clinical trials of beta blockers in heart failure due to systolic dysfunction\", section on 'Comparison with other beta blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Retrospective data suggest that some beta blockers other than those with proven benefit in randomized trials (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    but not short-acting",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    tartrate) may be beneficial in HF. However these observations are not sufficient to support a recommendation for use of beta blockers without benefit established by randomized studies.",
"   </p>",
"   <p>",
"    Patients with low blood pressure may tolerate",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    better than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    . Conversely, those with high blood pressure may have a greater lowering of blood pressure with carvedilol. In MERIT-HF, metoprolol succinate resulted in a higher blood pressure than placebo, presumably because of improved cardiac function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Guidelines and recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines recommend use of one of the beta blockers proven to reduce mortality (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    , extended release",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    succinate, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/29/2520?source=see_link\">",
"     bisoprolol",
"    </a>",
"    ) in all stable patients with current or prior symptoms of HF and reduced LVEF, unless contraindicated (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/1\">",
"     1",
"    </a>",
"    ]. The 2006 HFSA guidelines included a similar recommendation for patients with HF and LVEF &le;40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12905?source=see_link\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the absence of a contraindication, our recommendation is to offer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    succinate, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/29/2520?source=see_link\">",
"     bisoprolol",
"    </a>",
"    to patients with NYHA class II, III, or stable class IV HF with left ventricular ejection fraction less than 40 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Initiation of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the need for careful attention to initial dosing and the risk of transient worsening of symptoms, it is recommended that beta blocker therapy be initiated under the consultative guidance of an experienced HF center. Among inpatients, initiation of therapy prior to hospital discharge improves beta blocker use without an increase in side effects or drug discontinuation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/42\">",
"     42",
"    </a>",
"    ]. Prior to initiation of therapy, the patient should have no or minimal evidence of fluid retention and should not have required recent intravenous inotropic therapy.",
"   </p>",
"   <p>",
"    The patient should be informed that beta blockers may lead to an increase in symptoms for 4 to 10 weeks before any improvement is noted. Therapy should be begun at",
"    <strong>",
"     very low doses",
"    </strong>",
"    and the dose doubled every two weeks until the target dose is reached or symptoms become limiting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/43\">",
"     43",
"    </a>",
"    ]. Initial and target doses are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"       carvedilol",
"      </a>",
"      , 3.125 mg twice daily initially and 25 to 50 mg twice daily ultimately (the higher dose being used in subjects over 85 kg)",
"     </li>",
"     <li>",
"      For extended-release",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      (metoprolol succinate), 12.5 mg daily in patients with NYHA class III or IV or 25 mg daily in patients with NYHA II, and ultimately 200",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      If patients receive short acting metoprolol for cost reasons, dosing is not well established, but we recommend 6.25 mg twice daily initially and 50 to 100 mg twice daily ultimately.",
"     </li>",
"     <li>",
"      For",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/29/2520?source=see_link\">",
"       bisoprolol",
"      </a>",
"      , 1.25 mg once daily initially and 5 to 10 mg once daily ultimately.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Even lower starting doses should be given to patients with recent decompensation or a systolic pressure below 85 mmHg.",
"   </p>",
"   <p>",
"    Every effort should be made to achieve the target dose since the improvement appears to be dose-dependent. The proportion of patients who reach the target dose is higher in clinical trials than in the general population in which the patients are older and have more comorbid disease. However, although not optimal, even low doses appear to be of benefit and should be used when higher doses are not tolerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    What may be most important is the degree of beta blockade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/25\">",
"     25",
"    </a>",
"    ]. However, aiming for a particular resting heart rate or a particular reduction in heart rate is not of proven value [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The patient should weigh himself or herself daily and call the physician if there has been a 1 to 1.5 kg weight gain. Weight gain alone may be treated with diuretics, but resistant edema or more severe decompensation may require dose reduction or cessation (possibly transient) of the beta blocker. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12905?source=see_link\">",
"     \"Use of beta blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although data about the duration of beta blocker therapy in HF are lacking, it has been suggested that patients who are doing well should not have the beta blocker withdrawn, since clinical deterioration and sudden death or death from progressive HF has been observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Aldosterone antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     Spironolactone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    , which compete with aldosterone for the mineralocorticoid receptor, prolong survival in selected patients with HF as demonstrated in randomized controlled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/45-47\">",
"     45-47",
"    </a>",
"    ] (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28521?source=see_link\">",
"     \"Use of aldosterone antagonists in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    heart failure guidelines with 2009 focused update recommended addition of an aldosterone antagonist in selected patients with moderate to severe HF and reduced LVEF who can be carefully monitored for preserved renal function and a normal plasma potassium concentration (",
"    <a class=\"graphic graphic_table graphicRef81590 \" href=\"mobipreview.htm?40/1/40989\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/1\">",
"     1",
"    </a>",
"    ]. The subsequently published EMPHASIS-HF trial demonstrated benefit in selected patients with mild HF symptoms and reduced HF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28521?source=see_link&amp;anchor=H1107515#H1107515\">",
"     \"Use of aldosterone antagonists in heart failure\", section on 'Eplerenone in EMPHASIS-HF trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, we recommend aldosterone antagonist therapy to treat HF in patients who have NYHA functional class II HF and an LVEF &le;30 percent, or NYHA functional class III to IV HF and an LVEF &lt;35 percent, who can be carefully monitored for serum potassium and renal function. We also recommend aldosterone antagonist therapy for patients post ST elevation MI who are already receiving therapeutic doses of ACE inhibitor, have an LVEF &le;40 percent, and have either symptomatic heart failure or diabetes mellitus, who can be carefully monitored for serum potassium and renal function. The serum potassium should be &lt;5.0",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    and eGFR should be &ge;30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28521?source=see_link&amp;anchor=H15#H15\">",
"     \"Use of aldosterone antagonists in heart failure\", section on 'Our approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The endocrine side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    result from nonselective binding to androgen and progesterone receptors;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    has greater specificity for the mineralocorticoid receptor and therefore has a lower incidence of endocrine side effects (1 versus 10 percent in clinical trials). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28521?source=see_link\">",
"     \"Use of aldosterone antagonists in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    is associated with fewer endocrine side effects than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    (1 versus 10 percent in the respective trials), this advantage must be weighed against the marked difference in cost between the two drugs. It may be reasonable to begin with spironolactone (25 to 50",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    and switch to eplerenone (25 and after four weeks 50",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    if endocrine side effects occur. To the degree that blockade of a deleterious effect of aldosterone on the heart is important, a similar benefit would",
"    <strong>",
"     not",
"    </strong>",
"    be expected with other potassium-sparing diuretics (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    It is essential that serum potassium and creatinine be checked one to two weeks after starting",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5031?source=see_link\">",
"     eplerenone",
"    </a>",
"    and periodically thereafter. Patients with poor renal function are particularly at risk for hyperkalemia. The following are risk factors for life-threatening hyperkalemia:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increasing age",
"     </li>",
"     <li>",
"      More severe HF",
"     </li>",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      Underlying renal dysfunction",
"     </li>",
"     <li>",
"      Volume depletion",
"     </li>",
"     <li>",
"      Higher baseline plasma potassium concentration",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"       Spironolactone",
"      </a>",
"      dose &ge;50",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"     </li>",
"     <li>",
"      Higher ACE inhibitor or angiotensin II receptor blocker dose",
"     </li>",
"     <li>",
"      Combined use of ACE inhibitors and angiotensin II receptor blockers",
"     </li>",
"     <li>",
"      Concomitant beta blocker use",
"     </li>",
"     <li>",
"      Use of potassium supplements or potassium-containing salt substitutes",
"     </li>",
"     <li>",
"      Use of nonsteroidal anti-inflammatory drugs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Renal dysfunction, which is an important risk factor for hyperkalemia in this setting, may be underestimated by the serum creatinine concentration, especially in elderly patients and other patients with reduced lean body mass in whom creatinine production is reduced. Formulas are available to estimate glomerular filtration rate from a stable serum creatinine that take into account age and body mass. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link&amp;anchor=H20659769#H20659769\">",
"     \"Assessment of kidney function\", section on 'Estimation equations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27822027\">",
"    <span class=\"h2\">",
"     Angiotensin II receptor blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;ARBs for the treatment of HF appear to be as or possibly slightly less effective than ACE inhibitors when compared directly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. The CHARM-Alternative trial demonstrated benefit from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/48/38663?source=see_link\">",
"     candesartan",
"    </a>",
"    in patients with NYHA class II or III HF who could not tolerate ACE inhibitors, primarily because of cough [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines with 2009 update recommended an ARB in patients who cannot tolerate ACE inhibitors for this use and a class IIa recommendation for the use of an ARB as an alternative to ACE inhibitors, particularly in patients already taking an ARB for another indication (",
"    <a class=\"graphic graphic_table graphicRef81590 \" href=\"mobipreview.htm?40/1/40989\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/1\">",
"     1",
"    </a>",
"    ]. ARBs are more expensive than ACE inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/39/2680?source=see_link\">",
"     \"Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A separate issue, the value of adding an ARB to appropriate doses of an ACE inhibitor, was confirmed in the CHARM-Added trial for the composite outcome but not mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/51\">",
"     51",
"    </a>",
"    ]. The 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines concluded that the weight of evidence was less well established (",
"    <a class=\"graphic graphic_table graphicRef81590 \" href=\"mobipreview.htm?40/1/40989\">",
"     table 2",
"    </a>",
"    ) and the 2008 European Society of Cardiology guidelines recommended the addition of an ARB in persistently symptomatic patients with a reduced LVEF who are already being treated with conventional therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. However, the subsequently published EMPHASIS-HF trial demonstrated the efficacy of adding aldosterone antagonist (to ACE inhibitor and beta blocker therapy) in patients with NYHA class II or III HF and reduced systolic function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28521?source=see_link&amp;anchor=H1107515#H1107515\">",
"     \"Use of aldosterone antagonists in heart failure\", section on 'Eplerenone in EMPHASIS-HF trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, we recommend addition of an aldosterone antagonist (rather than an ARB) to ACE inhibitor and beta blocker therapy to treat HF in patients who can be carefully monitored for serum potassium and renal function who have NYHA functional class II HF and an LVEF &le;30 percent; or NYHA functional class III to IV HF and an LVEF &lt;35 percent; or are post-ST elevation MI, have an LVEF &le;40 percent, and have either symptomatic heart failure or diabetes mellitus. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Aldosterone antagonists'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The combination of aldosterone antagonist therapy and ACE inhibitor plus ARB therapy is",
"    <strong>",
"     not",
"    </strong>",
"    generally recommended. In patients who are appropriate candidates for ACE inhibitor plus aldosterone antagonist therapy, the addition of an ARB is",
"    <strong>",
"     not",
"    </strong>",
"    generally recommended. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/39/2680?source=see_link&amp;anchor=H17#H17\">",
"     \"Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use\", section on 'Combination with aldosterone antagonist'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon the above considerations and the VALIANT trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/52\">",
"     52",
"    </a>",
"    ], an ARB should",
"    <strong>",
"     NOT",
"    </strong>",
"    be added to an ACE inhibitor in the immediate post-MI setting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/30/26088?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27821874\">",
"    <span class=\"h2\">",
"     Hydralazine plus nitrates",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/57/15254?source=see_link\">",
"     Hydralazine",
"    </a>",
"    plus nitrate therapy may provide symptomatic and mortality benefit in selected patients with heart failure (HF) due to systolic dysfunction. Data supporting the efficacy of hydralazine plus nitrates in patients with HF due to systolic dysfunction are discussed separately (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/24/23942?source=see_link\">",
"     \"Hydralazine plus nitrate therapy in patients with heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In blacks, we recommend the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    plus oral nitrate therapy for patients with persistent NYHA class III to IV HF and LVEF &lt;40 percent despite optimal therapy including a beta blocker, ACE inhibitor (or ARB), aldosterone antagonist (if indicated) and diuretics. Although there is evidence of hemodynamic benefit in non-blacks as well as blacks, the strength of evidence of benefit of hydralazine plus nitrate therapy is stronger in blacks.",
"   </p>",
"   <p>",
"    We suggest treatment with a combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    plus nitrate in patients with HF and reduced LVEF who are unable to take both ACE inhibitor and ARB due to drug intolerance (including hyperkalemia), hypotension, or worsening renal insufficiency. ARB intolerance can be presumed in patients who develop hyperkalemia or renal insufficiency on ACE inhibitor therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27821914\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Starting doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    25 mg three times daily and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/22/36198?source=see_link\">",
"     isosorbide dinitrate",
"    </a>",
"    20 mg three times daily are recommended. Uptitration of dose should be considered every two to four weeks. The dose should not be increased if symptomatic hypotension develops. The target dose is hydralazine 75 mg three times daily and isosorbide dinitrate (40 mg three times daily). Although direct evidence of efficacy is lacking,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/24/19846?source=see_link\">",
"     isosorbide mononitrate",
"    </a>",
"    (40 to 120 mg daily) may be used in place of isosorbide dinitrate to improve compliance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Digoxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    is given to patients with HF and systolic dysfunction to control symptoms (such as fatigue, dyspnea, and exercise intolerance) and, in patients with atrial fibrillation, to control the ventricular rate. As demonstrated in the DIG trial, digoxin therapy was associated with a significant reduction in hospitalization for HF but no benefit in terms of overall mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, subsequent subgroup analyses suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    may have an effect on survival that varies with the serum digoxin concentration (SDC). Compared to placebo, survival was significantly improved when the SDC was between 0.5 and 0.8",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    in men and significantly worsened when the SDC was &ge;1.2",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef80620 \" href=\"mobipreview.htm?24/42/25262\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/54\">",
"     54",
"    </a>",
"    ]. A similar relationship was seen in women with a nonsignificant trend toward improved survival when the SDC was between 0.5 and 0.9",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    and significantly worse survival when the SDC was &ge;1.2",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/4/18504?source=see_link&amp;anchor=H11#H11\">",
"     \"Use of digoxin in heart failure due to systolic dysfunction\", section on 'Optimal digoxin level'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    for the treatment of symptoms in patients with left ventricular dysfunction was considered reasonable in the 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines with 2009 update (",
"    <a class=\"graphic graphic_table graphicRef81590 \" href=\"mobipreview.htm?40/1/40989\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/1\">",
"     1",
"    </a>",
"    ]. We suggest starting digoxin in patients with left ventricular systolic dysfunction (left ventricular ejection fraction [LVEF] &lt;40 percent) who continue to have NYHA functional class II, III, and IV symptoms (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"     table 4",
"    </a>",
"    ) despite appropriate therapy including an ACE inhibitor, beta blocker, an aldosterone antagonist if indicated, and an additional diuretic if necessary for fluid control. The usual daily dose of digoxin is 0.125 mg or less, based upon renal function. Based upon the data from the DIG trial correlating serum digoxin concentration and survival, we recommend maintaining the SDC between 0.5 and 0.8",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef80620 \" href=\"mobipreview.htm?24/42/25262\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    is",
"    <strong>",
"     NOT",
"    </strong>",
"    indicated as primary therapy for the stabilization of patients with acutely decompensated HF. Such patients should first receive appropriate treatment for HF, usually with intravenous medications. Digoxin may be initiated at the same time as part of a long-term treatment strategy to reduce risk of rehospitalization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     TREATMENT OF SUBGROUPS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Influence of gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meta-analyses have defined the role of ACE inhibitors and beta blockers in women with HF. A meta-analysis of ACE inhibitor trials suggested that the benefit from these drugs may not apply to women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/56\">",
"     56",
"    </a>",
"    ]. Among trials of ACE inhibitor therapy in symptomatic HF, the relative mortality risk with an ACE inhibitor was significantly reduced in men at 0.80 (95% CI 0.68-0.93) but showed only a trend toward significance in women at 0.90 (95 0.78-1.05). Until more definitive data are provided, ACE inhibitors should continue to be used in women with HF.",
"   </p>",
"   <p>",
"    In contrast, women appear to benefit from beta blockers to the same degree as men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. A pooled analysis from MERIT-HF, COPERNICUS, CIBIS II, and the United States",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     Carvedilol",
"    </a>",
"    Heart Failure trials found that the mortality benefit from beta blocker therapy was the same in men and women (relative risk 0.66 and 0.63, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Influence of race",
"    </span>",
"    &nbsp;&mdash;&nbsp;Race may affect the response to ACE inhibitors,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/22/36198?source=see_link\">",
"     isosorbide dinitrate",
"    </a>",
"    , and beta blockers in patients with HF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     ACE inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The V-HeFT trial and a matched cohort study from the SOLVD trial suggested that there were important differences between blacks and whites in the response to ACE inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. Two major findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blacks had higher rates of both progressive HF and overall mortality. In the SOLVD analysis, the respective values were 13 versus 8 per 100 patient-years in whites for hospitalization for HF and 12 versus 10 per 100 patient-years for overall mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Blacks had a lesser response than whites to ACE inhibition with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/19/8505?source=see_link\">",
"       enalapril",
"      </a>",
"      despite receiving similar doses. In the SOLVD matched cohort study, enalapril therapy in whites was associated with a significant 44 percent reduction in hospitalization for HF compared to placebo; in contrast, there was no significant reduction among blacks (",
"      <a class=\"graphic graphic_figure graphicRef71327 \" href=\"mobipreview.htm?27/17/27934\">",
"       figure 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The apparent lack of response in blacks has some biologic plausibility since similar findings have been noted in patients with hypertension. Blacks respond less well to ACE inhibitors than to most other antihypertensive drugs (",
"    <a class=\"graphic graphic_figure graphicRef65117 \" href=\"mobipreview.htm?37/22/38253\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/61\">",
"     61",
"    </a>",
"    ]. In the matched cohort study from SOLVD, there were significant reductions in systolic and diastolic pressure with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    in whites",
"    <span class=\"nowrap\">",
"     (5/3.6)",
"    </span>",
"    but not blacks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/14/15592?source=see_link\">",
"     \"Treatment of hypertension in blacks\"",
"    </a>",
"    .) In addition to genetic disparities, environmental differences (such as diet) could contribute to the varying response.",
"   </p>",
"   <p>",
"    In contrast to these findings, another analysis of the SOLVD trials using mortality as the end point found that the relative risk (RR) of death was reduced to the same degree in both blacks and whites (RR for blacks 0.89, 95% CI 0.74-1.06; RR for whites 0.89, 95% CI 0.82-0.97) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/56\">",
"     56",
"    </a>",
"    ]. The risk reduction was significant in whites but not blacks, an observation that is likely to be explained by the smaller number of blacks in the trials (800 versus 5718). Thus, ACE inhibitors should continue to be used in black patients with HF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting data on the efficacy of beta blockers in black patients. In the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     carvedilol",
"    </a>",
"    trials, the benefit of beta blockade was of similar magnitude in blacks and nonblack patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/62\">",
"     62",
"    </a>",
"    ]. In comparison, it appeared that blacks derived no benefit with bucindolol in the BEST trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of beta blocker trials in HF confirmed this distinction, finding different results depending upon whether or not the BEST data were included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/56\">",
"     56",
"    </a>",
"    ]. In the COPERNICUS, MERIT-HF, and United States",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/22/9577?source=see_link\">",
"     Carvedilol",
"    </a>",
"    Heart Failure trials, the reduction in all-cause mortality with beta blockers was the same for blacks and whites (relative risk 0.67 and 0.63, respectively). With inclusion of the data from BEST, the benefit of beta blockers remained significant for whites but was no longer significant in blacks (relative risk 0.69 and 0.97, respectively).",
"   </p>",
"   <p>",
"    These observations demonstrate that bucindolol, a beta blocker with partial beta agonist activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/64\">",
"     64",
"    </a>",
"    ], is not effective in reducing mortality in blacks. The reasons for this difference are not clear, but (as speculated by the authors of BEST) may include race-specific differences in the beta adrenergic pathway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Hydralazine with nitrates",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the V-HeFT trials, blacks had a lesser benefit from ACE inhibition than whites, while the benefit of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    -nitrate combination was more pronounced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/60\">",
"     60",
"    </a>",
"    ]. This observation led to the design of the A-HeFT trial (African-American Heart Failure Trial), in which black patients with class III to IV HF on standard heart failure therapy (including an ACE inhibitor if tolerated) were randomly assigned to a fixed combination of hydralazine and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/22/36198?source=see_link\">",
"     isosorbide dinitrate",
"    </a>",
"    or placebo. (See",
"    <a class=\"local\" href=\"#H27821874\">",
"     'Hydralazine plus nitrates'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Influence of diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic patients with HF are treated in the same fashion as nondiabetics. Data supporting this approach are available for both beta blockers and ACE inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28569?source=see_link&amp;anchor=H13#H13\">",
"     \"Heart failure in diabetes mellitus\", section on 'Therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The thiazolidinediones and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , which are often used in type 2 diabetics, are relatively contraindicated in patients with HF. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/3/42039?source=see_link\">",
"     \"Drugs that should be avoided or used with caution in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     OTHER DRUGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     N-3 polyunsaturated fatty acids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence from a randomized trial indicates that supplementation with N-3 polyunsaturated fatty acids (PUFA) in patients with HF can reduce mortality. The GISSI-HF investigators randomly assigned 6975 class II-IV chronic HF patients to 1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    n-3 PUFA or placebo with a median follow-up of 3.9 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/65\">",
"     65",
"    </a>",
"    ]. Death from any cause was reduced with n-3 PUFA compared to placebo from 29 to 27 percent (adjusted hazard ratio 0.91, 95.5% CI 0.833-0.998) and the endpoint of death or admission to the hospital for cardiovascular reasons was also reduced (59 to 57 percent, adjusted hazard ratio 0.92, 99% CI 0.849-0.999).",
"   </p>",
"   <p>",
"    The potential role of supplementation with N-3 polyunsaturated fatty acids for prevention of HF is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36330?source=see_link\">",
"     \"Fish oil and marine omega-3 fatty acids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials have evaluated the efficacy of statins on mortality in patients with both ischemic and nonischemic systolic HF. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/56/24453?source=see_link\">",
"     \"Statin therapy in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Summarized briefly, no benefit from statin therapy has generally been demonstrated in patients with moderate to severe heart failure due to systolic dysfunction with or without coronary artery disease. Limited data suggest that statins may benefit patients with diastolic dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Calcium channel blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some initial studies suggested a possible deleterious effect of calcium channel blockers in patients with HF, while later trials with vasoselective calcium channel blockers",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/45/2775?source=see_link\">",
"     felodipine",
"    </a>",
"    showed a neutral effect on mortality (",
"    <a class=\"graphic graphic_figure graphicRef70884 \" href=\"mobipreview.htm?14/28/14798\">",
"     figure 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef78557 \" href=\"mobipreview.htm?13/24/13709\">",
"     figure 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/7\">",
"     7",
"    </a>",
"    ]. Thus, there is",
"    <strong>",
"     NO",
"    </strong>",
"    direct role for these drugs in the management of HF. However, amlodipine and felodipine appear to be safe in patients with HF and can be used if treatment with a calcium channel blocker is necessary for another indication, such as angina or hypertension. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/46/30438?source=see_link\">",
"     \"Calcium channel blockers in heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Drugs to avoid",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of drugs should be avoided or used with caution in patients with HF. This issue is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/3/42039?source=see_link\">",
"     \"Drugs that should be avoided or used with caution in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     EXERCISE TRAINING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both chronic hypoperfusion and a reduction in physical activity lead to skeletal muscle dysfunction and exercise intolerance in patients with chronic HF. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/27/17847?source=see_link\">",
"     \"Skeletal muscle dysfunction and exercise intolerance in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Randomized controlled trials have shown that exercise training can lessen symptoms, increase exercise capacity, improve the quality of life, reduce hospitalization, and increase survival in patients with chronic HF. These improvements are additive to the benefits of ACE inhibitors and beta blockers. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3000?source=see_link\">",
"     \"Cardiac rehabilitation in patients with heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31417?source=see_link\">",
"     \"Components of cardiac rehabilitation and exercise prescription\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines recommend exercise training as an adjunctive approach to improve clinical status in patients with reduced LVEF and HF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/1\">",
"     1",
"    </a>",
"    ]. Based upon the available data, we recommend that cardiac rehabilitation be offered to patients with stable NYHA class II to III HF (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"     table 4",
"    </a>",
"    ) who do not have advanced arrhythmias and who do not have other limitations to exercise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/1\">",
"     1",
"    </a>",
"    ]. Exercise training should be used in conjunction with drug therapy. The beneficial effects of exercise are seen with high or low levels of training, and are apparent as early as three weeks after training. There are not enough data at present to recommend cardiac rehabilitation for patients with advanced HF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     SERIAL ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HF should be evaluated serially to assess status, the response to therapy, and potential need for changes in management. The 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines with 2009 update recommend that each visit should include assessment of ability to perform activities of daily living, volume status and weight, current use of alcohol, tobacco, illicit drugs, alternative therapies, and chemotherapy drugs, as well as diet and sodium intake (",
"    <a class=\"graphic graphic_table graphicRef50551 \" href=\"mobipreview.htm?2/56/2956\">",
"     table 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It was also considered reasonable to repeat measurement of left ventricular ejection fraction and structural remodeling in patients who have a change in clinical status, have experienced or recovered from a clinical event, or have received treatment that might significantly change these parameters. The efficacy of serial measurement of serum brain natriuretic peptide was considered less well established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF REFRACTORY HF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the majority of patients with HF due to systolic dysfunction respond to optimal medical therapy, some patients do not improve or experience rapid recurrence of symptoms. These patients have symptoms at rest or on minimal exertion and often require repeated prolonged hospitalizations for intensive management. Specialized strategies are generally considered for these patients, including continuous intravenous positive inotropic therapy, cardiac resynchronization therapy, extracorporeal ultrafiltration via hemofiltration, mechanical circulatory support, surgery, or cardiac transplantation (",
"    <a class=\"graphic graphic_table graphicRef68693 \" href=\"mobipreview.htm?15/22/15724\">",
"     table 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/63/38906/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/40/4743?source=see_link\">",
"     \"Management of refractory heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h1\">",
"     OTHER ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Heart failure disease management programs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because HF is a chronic disease which often leads to repeated hospitalization, and because many interventions (as described above) can influence morbidity and mortality, the expertise of those providing clinical care for a patient with HF may have a significant influence on outcomes. HF disease management is a multidisciplinary framework for the care of HF patients including discharge planning, patient education and frequent outpatient assessment. The impact of disease management and other strategies is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/2/37929?source=see_link\">",
"     \"Strategies to reduce hospitalizations in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Associated conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HF may have a variety of associated conditions that require therapy, each of which is discussed in detail elsewhere. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Supraventricular tachycardias, particularly atrial fibrillation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27097?source=see_link\">",
"       \"Tachycardia-mediated cardiomyopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24042?source=see_link\">",
"       \"Atrial fibrillation in patients with heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ventricular arrhythmias and risk for sudden cardiac death. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/47/21241?source=see_link\">",
"       \"Ventricular arrhythmias in heart failure and cardiomyopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/55/19322?source=see_link\">",
"       \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Use of cardiac pacemakers and cardiac resynchronization therapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/49/31510?source=see_link\">",
"       \"Overview of cardiac pacing in heart failure\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/56/18314?source=see_link\">",
"       \"Cardiac resynchronization therapy in heart failure: Indications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thromboembolism. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/56/7048?source=see_link\">",
"       \"Indications for antithrombotic therapy in heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anemia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/42/1705?source=see_link\">",
"       \"Impact of anemia in patients with heart failure\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/12/17601?source=see_link\">",
"       \"Patient information: Heart failure (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/41/36499?source=see_link\">",
"       \"Patient information: Medicines for heart failure (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/57/1939?source=see_link\">",
"       \"Patient information: Heart failure and atrial fibrillation (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/32/7684?source=see_link\">",
"       \"Patient information: Systolic heart failure (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33877?source=see_link\">",
"       \"Patient information: Heart failure (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27823757\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Management of heart failure (HF) due to systolic dysfunction includes correction of systemic factors, lifestyle modification, treatment of underlying cardiac disease, device (implantable cardioverter-defibrillator and cardiac resynchronization) therapy as indicated, as well as pharmacologic therapy to relieve symptoms and prolong survival. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'General principles'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment of the underlying cardiovascular disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of systolic HF is accomplished via appropriate combinations of the following agents: (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Pharmacologic therapy of HF'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with systolic HF and volume overload, we recommend diuretics (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Such patients should also restrict dietary sodium. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Diuretics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with HF with left ventricular systolic dysfunction (LVEF &le;40 percent), we recommend ACE inhibitor therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'ACE inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with systolic HF who do not tolerate ACE inhibitors, we recommend an ARB as an alternative that provides a similar survival benefit (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27822027\">",
"       'Angiotensin II receptor blockers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with current or prior HF and an LVEF &le;40 percent, we recommend therapy with a beta blocker (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We believe that clinicians should choose one of the beta blockers of proven benefit (including reduction in all-cause mortality) in randomized trials (ie,",
"      <a class=\"external\" href=\"file://www.uptodate.com/contents/carvedilol-drug-information?source=see_link\">",
"       carvedilol",
"      </a>",
"      , extended-release",
"      <a class=\"external\" href=\"file://www.uptodate.com/contents/metoprolol-drug-information?source=see_link\">",
"       metoprolol",
"      </a>",
"      &nbsp;succinate, or",
"      <a class=\"external\" href=\"file://www.uptodate.com/contents/bisoprolol-drug-information?source=see_link\">",
"       bisoprolol",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Beta blockers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who can be monitored for preserved renal function and a normal plasma potassium concentration and meet one of the following criteria, we recommend the addition of an aldosterone antagonist (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      or, if not tolerated,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5031?source=see_link\">",
"       eplerenone",
"      </a>",
"      ): NYHA functional class II HF and a left ventricular ejection fraction (LVEF) &le;30 percent; or NYHA functional class III to IV HF and an LVEF &lt;35 percent (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"       table 4",
"      </a>",
"      ); or post ST elevation myocardial infarction and already receiving therapeutic doses of ACE inhibitor, and an LVEF &le;40 percent, and either symptomatic heart failure or diabetes mellitus; (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Given the relative cost differences, we suggest spironolactone rather than eplerenone for initial therapy, with switch to eplerenone if endocrine side effects occur (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Aldosterone antagonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The combination of aldosterone antagonist therapy and ACE inhibitor plus ARB therapy is",
"      <strong>",
"       not",
"      </strong>",
"      generally recommended.",
"     </li>",
"     <li>",
"      For black patients with persistent moderate to severe HF symptoms and left ventricular ejection fraction &lt;40 despite optimal therapy including a beta blocker, ACE inhibitor (or ARB), and aldosterone antagonist (if indicated) and other diuretics, we recommend the addition of the combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      and an oral nitrate (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27821874\">",
"       'Hydralazine plus nitrates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For select non-black patients with left ventricular ejection fraction &lt;40, particularly those with low output syndromes, hypertension, or mitral regurgitation with persistent symptoms despite optimal therapy including a beta blocker, ACE inhibitor (or ARB), and aldosterone antagonist (if indicated) and other diuretics, we suggest the addition of the combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      and an oral nitrate (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27821874\">",
"       'Hydralazine plus nitrates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with systolic HF who are unable to take an ACE inhibitor or ARB due to drug intolerance, hypotension or renal insufficiency, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      plus a nitrate (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27821874\">",
"       'Hydralazine plus nitrates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with left ventricular systolic dysfunction (LVEF &lt;40 percent) who continue to have NYHA functional class II, III, and IV symptoms (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"mobipreview.htm?3/2/3117\">",
"       table 4",
"      </a>",
"      ) despite optimal therapy (eg, ACE inhibitor or ARB, beta blocker, aldosterone antagonist and, if necessary for fluid control, a diuretic) we suggest administration of",
"      <a class=\"external\" href=\"file://www.uptodate.com/contents/digoxin-drug-information?source=see_link\">",
"       digoxin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Digoxin'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with stable NYHA functional class II to III, we recommend an exercise training program (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H39\">",
"       'Exercise training'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with HF should be evaluated serially to assess status, the response to therapy, and potential need for changes in management.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/1\">",
"      Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119:e391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/2\">",
"      Jessup M, Brozena S. Heart failure. N Engl J Med 2003; 348:2007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/3\">",
"      Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29:2388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/4\">",
"      Fonarow GC, Adams KF Jr, Abraham WT, et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 2005; 293:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/5\">",
"      Arnold JM, Liu P, Demers C, et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol 2006; 22:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/6\">",
"      Heart Failure Society of America, Lindenfeld J, Albert NM, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010; 16:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/7\">",
"      Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation 1997; 96:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/8\">",
"      Pickering TG, Herman L, Devereux RB, et al. Recurrent pulmonary oedema in hypertension due to bilateral renal artery stenosis: treatment by angioplasty or surgical revascularisation. Lancet 1988; 2:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/9\">",
"      Bloch MJ, Trost DW, Pickering TG, et al. Prevention of recurrent pulmonary edema in patients with bilateral renovascular disease through renal artery stent placement. Am J Hypertens 1999; 12:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/10\">",
"      Messerli FH, Bangalore S, Makani H, et al. Flash pulmonary oedema and bilateral renal artery stenosis: the Pickering syndrome. Eur Heart J 2011; 32:2231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/11\">",
"      Pelta A, Andersen UB, Just S, B&aelig;kgaard N. Flash pulmonary edema in patients with renal artery stenosis--the Pickering Syndrome. Blood Press 2011; 20:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/12\">",
"      Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113:e463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/13\">",
"      Rocha-Singh KJ, Eisenhauer AC, Textor SC, et al. Atherosclerotic Peripheral Vascular Disease Symposium II: intervention for renal artery disease. Circulation 2008; 118:2873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/14\">",
"      Bortman G, Sellanes M, Odell DS, et al. Discrepancy between pre- and post-transplant diagnosis of end-stage dilated cardiomyopathy. Am J Cardiol 1994; 74:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/15\">",
"      Marwick TH. The viable myocardium: epidemiology, detection, and clinical implications. Lancet 1998; 351:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/16\">",
"      Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002; 39:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/17\">",
"      Repetto A, Dal Bello B, Pasotti M, et al. Coronary atherosclerosis in end-stage idiopathic dilated cardiomyopathy: an innocent bystander? Eur Heart J 2005; 26:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/18\">",
"      Koelling TM, Aaronson KD, Cody RJ, et al. Prognostic significance of mitral regurgitation and tricuspid regurgitation in patients with left ventricular systolic dysfunction. Am Heart J 2002; 144:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/19\">",
"      Young JB, Gheorghiade M, Uretsky BF, et al. Superiority of \"triple\" drug therapy in heart failure: insights from the PROVED and RADIANCE trials. Prospective Randomized Study of Ventricular Function and Efficacy of Digoxin. Randomized Assessment of Digoxin and Inhibitors of Angiotensin-Converting Enzyme. J Am Coll Cardiol 1998; 32:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/20\">",
"      Fonarow GC, Yancy CW, Hernandez AF, et al. Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. Am Heart J 2011; 161:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/21\">",
"      Willenheimer R, van Veldhuisen DJ, Silke B, et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005; 112:2426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/22\">",
"      Sliwa K, Norton GR, Kone N, et al. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure. J Am Coll Cardiol 2004; 44:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/23\">",
"      Fang JC. Angiotensin-converting enzyme inhibitors or beta-blockers in heart failure: does it matter who goes first? Circulation 2005; 112:2380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/24\">",
"      Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996; 94:2807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/25\">",
"      Wikstrand J, Hjalmarson A, Waagstein F, et al. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol 2002; 40:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/26\">",
"      Faris R, Flather MD, Purcell H, et al. Diuretics for heart failure. Cochrane Database Syst Rev 2006; :CD003838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/27\">",
"      Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med 1992; 327:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/28\">",
"      Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/29\">",
"      Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987; 316:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/30\">",
"      Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991; 325:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/31\">",
"      Flather MD, Yusuf S, K&oslash;ber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/32\">",
"      Kostis JB, Shelton BJ, Yusuf S, et al. Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the Studies of Left Ventricular Dysfunction. Am Heart J 1994; 128:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/33\">",
"      Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100:2312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/34\">",
"      Delahaye F, de Gevigney G. Is the optimal dose of angiotensin-converting enzyme inhibitors in patients with congestive heart failure definitely established? J Am Coll Cardiol 2000; 36:2096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/35\">",
"      Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med 2001; 134:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/36\">",
"      Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/37\">",
"      Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/38\">",
"      Goldstein S, Fagerberg B, Kjekshus J, et al. Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study. J Am Coll Cardiol 2001; 38:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/39\">",
"      Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/40\">",
"      Exner DV, Dries DL, Waclawiw MA, et al. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1999; 33:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/41\">",
"      Cleland JG, McGowan J, Clark A, Freemantle N. The evidence for beta blockers in heart failure. BMJ 1999; 318:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/42\">",
"      Gattis WA, O'Connor CM, Gallup DS, et al. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. J Am Coll Cardiol 2004; 43:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/43\">",
"      Eichhorn EJ, Bristow MR. Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure. Am J Cardiol 1997; 79:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/44\">",
"      Gullestad L, Wikstrand J, Deedwania P, et al. What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF). J Am Coll Cardiol 2005; 45:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/45\">",
"      Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/46\">",
"      Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/47\">",
"      Pitt B, White H, Nicolau J, et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005; 46:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/48\">",
"      Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/49\">",
"      Jong P, Demers C, McKelvie RS, Liu PP. Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J Am Coll Cardiol 2002; 39:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/50\">",
"      Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/51\">",
"      McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/52\">",
"      Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349:1893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/53\">",
"      The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997; 336:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/54\">",
"      Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003; 289:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/55\">",
"      Adams KF Jr, Patterson JH, Gattis WA, et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol 2005; 46:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/56\">",
"      Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003; 41:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/57\">",
"      Ghali JK, Pi&ntilde;a IL, Gottlieb SS, et al. Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Circulation 2002; 105:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/58\">",
"      Exner DV, Dries DL, Domanski MJ, Cohn JN. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 2001; 344:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/59\">",
"      Dries DL, Exner DV, Gersh BJ, et al. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med 1999; 340:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/60\">",
"      Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail 1999; 5:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/61\">",
"      Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993; 328:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/62\">",
"      Yancy CW, Fowler MB, Colucci WS, et al. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med 2001; 344:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/63\">",
"      Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001; 344:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/64\">",
"      Andreka P, Aiyar N, Olson LC, et al. Bucindolol displays intrinsic sympathomimetic activity in human myocardium. Circulation 2002; 105:2429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/63/38906/abstract/65\">",
"      Gissi-HF Investigators, Tavazzi L, Maggioni AP, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372:1223.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3508 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-E4AAF914B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_63_38906=[""].join("\n");
var outline_f37_63_38906=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27823757\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Chronic versus acute decompensated HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Major society guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20200800\">",
"      Goals of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20200745\">",
"      Components of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TREATMENT OF THE UNDERLYING CARDIOVASCULAR DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Drug therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Renovascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Ischemic heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Valvular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PHARMACOLOGIC THERAPY OF HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Order of therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - ACE inhibitors or beta blockers first",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Diuretics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ACE inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Impact of aspirin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Choice of agent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Guidelines and recommendation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Aldosterone antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27822027\">",
"      Angiotensin II receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27821874\">",
"      Hydralazine plus nitrates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27821914\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Digoxin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      TREATMENT OF SUBGROUPS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Influence of gender",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Influence of race",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - ACE inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Hydralazine with nitrates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Influence of diabetes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      OTHER DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      N-3 polyunsaturated fatty acids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Statins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Drugs to avoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      EXERCISE TRAINING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      SERIAL ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      MANAGEMENT OF REFRACTORY HF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      OTHER ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Heart failure disease management programs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Associated conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27823757\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3508\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3508|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/3/41021\" title=\"figure 1\">",
"      Carvedilol LVEF dose response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/15/11517\" title=\"figure 2A\">",
"      ACE inhibitor in LV dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/28/10701\" title=\"figure 2B\">",
"      ACE inhibitor moderate HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/61/23517\" title=\"figure 2C\">",
"      ACE inhibitor advanced HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/9/28829\" title=\"figure 3\">",
"      Mortality HF ACE beta block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/42/25262\" title=\"figure 4\">",
"      Digoxin level and survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/17/27934\" title=\"figure 5\">",
"      ACEIs in HF in blacks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/22/38253\" title=\"figure 6\">",
"      Response to antihypertensives in blacks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/28/14798\" title=\"figure 7\">",
"      Amlodipine in HF I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/24/13709\" title=\"figure 8\">",
"      Felodipine in HF V HeFT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3508|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/30/36331\" title=\"table 1\">",
"      Factors contributing to HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/1/40989\" title=\"table 2\">",
"      ACC AHA Rx systolic HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/45/42716\" title=\"table 3\">",
"      ACC AHA Rx HF other diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/2/3117\" title=\"table 4\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/22/15724\" title=\"table 5\">",
"      ACC AHA Rx refractory HF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/56/2956\" title=\"table 6\">",
"      ACC AHA serial assessment HF",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16090?source=related_link\">",
"      ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/39/2680?source=related_link\">",
"      Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/30/26088?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/30/24042?source=related_link\">",
"      Atrial fibrillation in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/46/30438?source=related_link\">",
"      Calcium channel blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/59/3000?source=related_link\">",
"      Cardiac rehabilitation in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/56/18314?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/0/19465?source=related_link\">",
"      Causes of dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/43/8888?source=related_link\">",
"      Cheyne-Stokes breathing and obstructive sleep apnea in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31417?source=related_link\">",
"      Components of cardiac rehabilitation and exercise prescription",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/3/24633?source=related_link\">",
"      Diagnosis and management of ischemic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/3/42039?source=related_link\">",
"      Drugs that should be avoided or used with caution in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/26/7592?source=related_link\">",
"      Endomyocardial biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/8/15497?source=related_link\">",
"      Epidemiology and causes of heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/23/7544?source=related_link\">",
"      Evaluation of acute decompensated heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/41/10905?source=related_link\">",
"      Evaluation of hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36330?source=related_link\">",
"      Fish oil and marine omega-3 fatty acids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/36/9799?source=related_link\">",
"      Functional mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/57/28569?source=related_link\">",
"      Heart failure in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/24/23942?source=related_link\">",
"      Hydralazine plus nitrate therapy in patients with heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/42/1705?source=related_link\">",
"      Impact of anemia in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34297?source=related_link\">",
"      Indications and contraindications for cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/56/7048?source=related_link\">",
"      Indications for antithrombotic therapy in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/57/37785?source=related_link\">",
"      Intermediate- and long-term mechanical cardiac support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/34/1577?source=related_link\">",
"      Management of heart failure in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/40/4743?source=related_link\">",
"      Management of refractory heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/49/31510?source=related_link\">",
"      Overview of cardiac pacing in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/28/3529?source=related_link\">",
"      Overview of the care of patients with stable ischemic heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33877?source=related_link\">",
"      Patient information: Heart failure (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/12/17601?source=related_link\">",
"      Patient information: Heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/57/1939?source=related_link\">",
"      Patient information: Heart failure and atrial fibrillation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/61/39890?source=related_link\">",
"      Patient information: Low sodium diet (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/41/36499?source=related_link\">",
"      Patient information: Medicines for heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/32/7684?source=related_link\">",
"      Patient information: Systolic heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/27/36282?source=related_link\">",
"      Rationale for and clinical trials of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/62/15338?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/55/19322?source=related_link\">",
"      Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/27/17847?source=related_link\">",
"      Skeletal muscle dysfunction and exercise intolerance in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/56/24453?source=related_link\">",
"      Statin therapy in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/2/37929?source=related_link\">",
"      Strategies to reduce hospitalizations in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27097?source=related_link\">",
"      Tachycardia-mediated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7018?source=related_link\">",
"      Treatment and prognosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/42/33446?source=related_link\">",
"      Treatment of acute decompensated heart failure in acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/7/41079?source=related_link\">",
"      Treatment of acute decompensated heart failure: General considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/54/8040?source=related_link\">",
"      Treatment of bilateral atherosclerotic renal artery stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/14/15592?source=related_link\">",
"      Treatment of hypertension in blacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/22/29031?source=related_link\">",
"      Treatment of hypertension in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/43/29369?source=related_link\">",
"      Treatment of unilateral atherosclerotic renal artery stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28521?source=related_link\">",
"      Use of aldosterone antagonists in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12905?source=related_link\">",
"      Use of beta blockers in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/4/18504?source=related_link\">",
"      Use of digoxin in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/55/3962?source=related_link\">",
"      Use of diuretics in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/47/21241?source=related_link\">",
"      Ventricular arrhythmias in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_63_38907="Treatment of retained placenta by etiology";
var content_f37_63_38907=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of retained placenta by etiology",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type of Retained placenta",
"       </td>",
"       <td class=\"subtitle1\">",
"        Partial accreta",
"       </td>",
"       <td class=\"subtitle1\">",
"        Placenta adherens",
"       </td>",
"       <td class=\"subtitle1\">",
"        Trapped placenta",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Patho-physiology",
"        </strong>",
"       </td>",
"       <td>",
"        Disruption of placenta-myometrial interface",
"       </td>",
"       <td>",
"        Persistent placental inhibition of myometrial contraction",
"       </td>",
"       <td>",
"        Loss of gravitational forces or cervical closure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Etiological factor",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Pre-eclampsia",
"        </p>",
"        <p>",
"         Small placenta",
"        </p>",
"        <p>",
"         Previous abortion",
"        </p>",
"        <p>",
"         Previous uterine injury",
"        </p>",
"        <p>",
"         Uterine abnormalities",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Prematurity",
"        </p>",
"        <p>",
"         Augmented or dysfunctional labor",
"        </p>",
"        <p>",
"         Induced labor",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Delivery in a labor bed",
"        </p>",
"        <p>",
"         Use of prophylactic IV ergometrine",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Treatment",
"        </strong>",
"       </td>",
"       <td>",
"        Manual removal, conservative management",
"       </td>",
"       <td>",
"        Manual removal, pharmacologic therapy",
"       </td>",
"       <td>",
"        Controlled cord traction, nitroglycerin for uterine relaxation if no atony",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Model for a classification of etiological factors for a prolonged third stage with suggested optimal treatment.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_63_38907=[""].join("\n");
var outline_f37_63_38907=null;
var title_f37_63_38908="Laboratory findings inborn errors of metabolism";
var content_f37_63_38908=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Distinguishing biochemical findings of inborn errors of metabolism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Findings",
"       </td>",
"       <td class=\"subtitle1\">",
"        MSUD",
"       </td>",
"       <td class=\"subtitle1\">",
"        OA",
"       </td>",
"       <td class=\"subtitle1\">",
"        UCD",
"       </td>",
"       <td class=\"subtitle1\">",
"        DCM",
"       </td>",
"       <td class=\"subtitle1\">",
"        FAO",
"       </td>",
"       <td class=\"subtitle1\">",
"        MD",
"       </td>",
"       <td class=\"subtitle1\">",
"        PD",
"       </td>",
"       <td class=\"subtitle1\">",
"        LSD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metabolic acidosis",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory alkalosis",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperammonemia",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoglycemia",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ketones",
"       </td>",
"       <td>",
"        A/H",
"       </td>",
"       <td>",
"        H",
"       </td>",
"       <td>",
"        A",
"       </td>",
"       <td>",
"        A/H",
"       </td>",
"       <td>",
"        A/L",
"       </td>",
"       <td>",
"        A/H",
"       </td>",
"       <td>",
"        A",
"       </td>",
"       <td>",
"        A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lactic acidosis",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MSUD: maple syrup urine disease; OA: organic acidemias; UCD: urea cycle disorders; DCM: disorders of carbohydrate metabolism; FAO: fatty acid oxidation disorders; MD: mitochondrial disorders; PD: peroxisomal disorders; LSD: lysosomal storage disorders; -: usually absent; &plusmn;: sometimes present; +: usually present; ++: always present; A: appropriate; H: inappropriately high; L: inappropriately low.",
"     <br>",
"      * Within disease categories, not all diseases have all findings; for disorders with episodic decompensation clinical and laboratory findings may be present only during acute crisis; for progressive disorders, findings may not be present early in the course of disease.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Weiner DL. Metabolic Emergencies. In: Textbook of Pediatric Emergency Medicine, 5th ed, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2006. p.1193.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_63_38908=[""].join("\n");
var outline_f37_63_38908=null;
var title_f37_63_38909="Risk model SCD HCM";
var content_f37_63_38909=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75731&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75731&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Risk of sudden death in HCM",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 423px; height: 374px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A set of four predictors of sudden death were analyzed to develop a risk stratification algorithm in a study of 368 patients with hypertrophic cardiomyopathy (HCM). The predictors included a history of syncope and/or a family history of sudden death, a left ventricular wall thickness &ge;30 mm, non-sustained ventricular tachycardia on ambulatory monitoring, and an abnormal blood pressure response to exercise (see text). This bar graph shows the percentage of each risk factor group (zero, one, two and three risk factors) in which patients died during follow-up (black bars = sudden death; hatched bars = congestive cardiac failure or transplant; white = all deaths). The majority of deaths were sudden, and the greatest proportion occurred in patients with multiple risk factors.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Elliott, PM, Poloniecki, J, Dickie, S, et al. J Am Coll Cardiol 2000; 36:2212.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_63_38909=[""].join("\n");
var outline_f37_63_38909=null;
var title_f37_63_38910="Fascial interposition during vasectomy illustration";
var content_f37_63_38910=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F66760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F66760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fascial interposition during vasectomy illustration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 448px; height: 394px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGKAcADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiioLm5S3X5uWPRR1NDdhpNuyJXdUUs7BQO5qlNqHaBN3+03Aqm7STvvmP0XsKz/EGu6V4c05r7W72CytVO3fKfvH0A6k+w5rNyOmFFLfVmt9ruj3T/vmporx0/4+Qqp/fHAH1rkPAPjTTfHFrd3Wiw3gtbebyfNuItiynGcpycjkdcHmum1jamlTBv4xsA+tJPS5cqa5lBrU2KK5bwvq5Eg068f5h/qXY/eH936+ldTVxkpK6OarSlSlyyCiiiqMwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAIrmYQRFzyegHqayhudzJKcu36VLeyGW7K/wAEfA+tcl8Q9L8SazpCWPhXVbbSmlYi4uHVjIEx0jI6H34PoRWUmdlGCSV+p438a/jRq2l+JJ9D8I3EECWmEnuwiys0ndV3AgAdDxnOemK8uePxr8SvFWnadq0l9dXcmAhni2JDGT80m0AADHJOOcAc8V7v4F+Aem6Brltq2rapNqtzbuJUi8kRxiQc7m5JbB57e9e4Qw5OWrNQctzuliadFWpq/mZ3hLw/Y+HdEtNL0yERWlsgRR3Pqx9STkk+9Vtcu/tEwjjP7qP9T61o6jefKYbc8dGYfyFYkkdVN6WRlhoNy9pPcydQhLKHQkOpyCOoNdb4V1r+07YxTkC8iGHH94f3h/WsCRPWs91msrpLu0bbLGcj39j7VEZcrOmvRVeFuvQ9Moqlo+oRanYpcRHBPDr3Vu4q7XUnc8KUXF2YUUUUCCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDH2k3UwPXcaspBxk0uoQybTPbAGUDlT/EP8a5TVNZ1ExkQOsQ77V5/Wsm1Hc76dOVde4dRcXFtZrmeRVJ6L3P4VlXOpPcfKg2Renc/WuFW6kE5eZ2dieWY5JrobC4EkY5rN1LnXDCRhq9WaycinNHkVHA1XowCKa1Im+VmbNDiqUsfUEVuyxjFZ1xFzUyia0qtzK026k0bUROuTbucSoO49fqK9ChlSeJJYmDxuMqw7iuDniDKVIq34X1E2Fz9huW/0eRv3bH+Fj2+h/nVU52dmZYzD+0XtI7o7Siiiug8gKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACue8Q6YCGuYV4/5aKP510NBGRzUyjzKxrRqypS5keT6taYUunSodKvDE4VjxXY6/pfkOzouYHP/fJ9K4zUbQwvuQcVytOLse/TqRqx5onW2soZQQa0IZK5HRrzACOa6KGTOKqLMatM1gdwqtcR5p0D1O67hWm5x/AzEnjwTWdeQCWMjvW/cRdeKzZo8VlJHdSqXNrwrqjXluba5bN1COp6uvY/X1rerziUy2s6XNsdssZyPf2PtXeaXfRajZR3EJ4YYZf7rdwa2pzurM8zGYf2cueOzLdFFFanEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFADJokmiaOQZRhgiuI1rTWt5GiflTyjeoruqq6jZpe25jfhhyrehqJw5kdWFxDoy12Z5JKj2s2a39KvRKoB603VrA7nSRdsinBrBt5Htbj0wa5dj3NJI7+2cYq6jA1z1jd+YgINacE3vWsZHDVpMvSKCKzrmOr6vuFQTrmm9TOm3FmPKnUGo9Gvjo+pfOf8ARJyFk9FPZv8APars6Vn3UIkjZTWezujtaVWPLLqehA5GRyKK5jwfqTyI2n3JzJCMxsf4k9Pw/lXT11RlzK54VWm6UnFhRRRTMwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAydd0/7TF50S/vkHQfxCuC1OyDZdRzXqdcv4h07ypDPGP3Tn5h/dNYVYdUengcR/y7l8ji9PuWhk2N0rpbeXKgg1zuo23lNvXpVjSrzPyMeaxTPTlG6Oqhk6VZwGHFZUEnStO3bIrWLucFWPLqQzxcdKzZkwTW7MuRWXcpyaUkXRmY82+CWO5tztljO4Gu70m+j1GxjuIuM8Mv91u4rjpUyCKTQdROkalsmOLScgN6K3Zv8aKcuV2YYuh7WHMt0d9RRRXSeKFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABTJ4kmieOQZVhg0+igE7ao4TV7BoJXgkGR1U+o9a5iRGtp+OOa9T1iy+2Wx2481OVPr7Vwt/bb1YFcMOtcs48rPewtf20NdySwuRIoyea27WWuMt5Gt5gDwM10djOGUEGpizSrC6OgB3LVW4j60sMlWGXeta7nB8DMaWPFZmoQCSI8c10FxHWbOnWs5I7aU7mv4N1U3tkbWc/6TbAL/vL2P8AT/8AXXRV5pDI+manDeRZwrfOB/Ep6ivSIZEmiSWJgyOAykdwa3pyurHl42j7OfMtmPooqO4nit4jJPIsaDqzHArQ4ySisS68R2sQPkpJNjuBtX8z/hSW+pahPhpLSK0hI4aVizH6KACf0oA3KKz9N1AXU80GQzxBWLBSoOc9iT6VoUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVzviKwwxuoh8p++B2PrXRUjqHUqwBUjBB71Mo8ysa0arpT5keVanbEfOtLpFyVbY1dDrWn/ZZ2TGYn5Q+3pXMXCfZpcjgVyNWZ9BCaqRutmdXbS5xWnDJxiuY026EiDnmtqCTpWkWctamXJ03Cs64irTVty1BOoqmrmNOTi7GDdRb0YVr+CtQJWTTpj80eXjJ/u55H4H+dUrhME1mSySWN5FeW/EkZz9fUVnF8rudVWmq1PlPSq53xRaxSXFtNcSTrGP3alACqsfUH19fatuxuo7y0iuITmORcj29qS/8AINpIt2AYWGGB7+w966zwWmnZmVp2lQRbZEBd+0kzA7fcKOKvXLQ28Lsz7pCOWY81yEw1G2u1t7NiFkciONzkqo9TSppF7q95dWV1eyRokZDPDgbWPTGeuPegEruzMbUvGl14cvZZNP8ADup62bjgtaIWSEKTkuVDNzuGAFPQ103hfxrFrGn+ZJbTfakP76KOMp5eScArJtYceoHeq3g2zW5tLiGRzDqtjIbadk+USYJAfb2zg/lW8ILm2fMmy4TvgYalGSkrl1aUqU3CW6LCa1bEjzEni/348/yzV23uYLgZgmjkx12sDiqqm3njz5Zqjd2EJYSKjK46MDgj8RzRcnlbN6isSxv5oLlLe8bdG/ypIeoPYH1z61t0yQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooArX9qt3bNE2MnlT6GuA1ezcb43XEiHBFekVieI7HzYvtKD50GH9x6/hWVSF1c78FX5Jcj2Z5zZzNbz4PAzXU2s25QQa5/U7bZJvUVb0q5yoVjzXOj15K6OnhkqWQgis2GXpVtG3LWqZxThZ3K1wM1n3EYdCDV+9mit0LzOFUetVodPutVj3oTZ2Z5M0g5Yf7I/rU2behsqkYRvJ2QnhXV5LSafTooXuHb95Gq9FPfJ7D/Peuk8tkDXF2/mTAHLD7sXso9feqltHZ6RZFLXEERPzzSH55D7n/PtWwIROsZJ/drzs7Z963horHk4n35e0SsmU9KtS9y95Im3I2xqeoWjSnVDduF+Z5jWhPIVGxeDWRcXlroti9xqEohi3nkgkknsAOpqmzKMLnMWFz/Z3xV12K4cRQ31hFegk4X938h/qa6JfEmi+W7jUbbCDJ+bn8B1P4V5V8Q9el1e8tdW0SzulFiskM0oGd8MgwwIHA4yeT3rY8MeE4dQ0dNT1K7+yW78puAXK+pJ6ZrnhKzcT2MVSU6dOs+qUX6x0/KzOs07xNLq2pomkaXNJZ7wst1I2xQO5Axz9OtdUcEYPSsDw7FZ2FmttoxuLyIuSZXY+WvrhsY/BQeetbE8owVX8TWqeh504WlZKxDPbrdWjoRkj+Vcxq+ua1pKiaJ0uIYz5ciypn6HIweQfzrqYJNkgJ6Hg1jalCk8Wr78eWsZU/ULnP5n9Kiq3yaPUUYqNTVXTG6H470++KxXymynPGWOYyf97t+P5116sGUMpBUjII5zXgs1uG5Fa/hnxReaDIIpN09l3hY/d91Pb6dK5aON6VDprYFb0/uPZKKpaRqdrq1kl1ZSb424IPBU+hHY1dr0E01dHmtNOzCiiimIKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACmuNyMMA5GMGnUUAcBqllcoC0drLcW7DIaJdxU9wR1GKxIoL1Zh5NheNz2hb/CvQr50srgl8qkpyrjjnuP61LFMHA2zsf8AgVYumrnpU8bPl2ucva2esSqCmnMo9ZHVf0zmryaZqP8Ay9Xdpar6IDI39K3GTcfmkY/VjQIox0xQoJEyxM5eXyMy20uxglWby5Lu4HIkuDkA+oXp+lc/Y69qlhrNxp/jGW0CMDNZ3kSmOORc/dKknDDgdfT1Ge2wgHNcP8Vp3ttCttTtM+dpt3Fcnb3QNhh9OQfwpVPdjzLob4HlrVVSmr82l3un0t89Dcsbae8uv7Qk2wxnAgjmiJdUH8XJ+Ut6YzjGfQb1rMPM2dj0+tZUV6LuJJYGDxSKGVl5BB6GrcCMMMeMc1UdNjmqtz+ItT/LcfN0bpTLi3guY/LuYY5kznbIoYZ+hqW8HmQBx25/Cs6aVYYy8jEIOuAT/KqbsZQi5JW3LX2W2W2e38mJbdwVaMKApBGCMVx3w+jit9R1vTmLzNplzsgEjE+VG2SoGe5HJPU5rb/tnT0l8trqMS/88ud//fPX9K5nRrqK0+K2pAlo4dYs45IjIjJ5kkXylV3AZO3msZSXNFnpYejP2NWDvtdfJr9Lna3NjFK7yAyxM/LGKVkyfUgHBNMSMxqFLu+O7Yz+grRIyKzr+dYBj70pHyoDyf8AAe9atJanBGo3oyvfzmGLbFgzP8qA9vc+wrB8Q3QsNJ+yIxM1x94nrtzkk/U/1rRmZbONru8bdK3AHr6KPQVyGrSyXkjTyHL+noPQVxYippZHTQpc75nsjMqpegbferLsFUk1nTyeY3tXnI7i3oWrX+j3LS6fLsLDDKRlW+oro4PiBrMRHmxWso75Qg/oa5q0jwMkVYMYbtWsa04aRZnOjCbvJHb6f8Rrd2C39lJF/txNvH5HH9a6/S9WsdVi8ywuY5gOoBwy/UHkV4o9tnoKhVZreQSQu8ci9GQkEfjXRDGzXxanNUwUJfDoe/0V5hoHj26tdkOrobiEceavDj69j+hr0DStXsNVTdYXMcuBkqDhl+oPIrvp14VNmefVoTpfEi/RRRWxiFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVkeJtbi0PTjO+Gmb5Yo/7zf4ClKSirsqMXJ8qDXbm3aKSxba88kZcKf4RnAY+nPT6VhWdnLJBHLa3TDjlH5we4rm/C+oy3uu3Mt5IXmuYzyfUYOB7YBroLNLm3Mj2w8wBzvj7g5zkfhXPRq+1uzpqUvYNJl4w6kvRo2/E0Imo7udop0WtIBiQFW9GGKnXWLc9ZEH41qALbXTIWmlCKBknsBSmwtL20dJHhuLeVSjgsGVgeCKgfU1aRybyRUP3ViReB7kg5P5VAg07e8qWKzzuMNLMu92Hpk9vbpRqxpxjq3r5f0jnJtPf4f6laLpU2/SNRmFuttcyEpbzMflKnk4749j7EdY1jE/zX0jXcnfzf9WP91Puj9T7mvOfGpubfxNpM99Bft4ctysypEDIkdwGO0sOoUAjA/Aeld7bRvfQxzibfDIodSvQg9Kxha7j2PTxjl7OnWveUlrLvrs33S3+V7nQaa8bwGFdoVeAo7CqV5blt0RkdOeqHBI+tTaXGkE21R94YzUmqvFCqySyInb5mAzW+6PKUnCp6lK2t4bZSIIwuTlj1LH1J6k+5rF8d6J/behMYJRb6jZsLmzuC23y5F5HPYHp+var7Xzy/LZwsSf45BtX8up/SopYY49suqXO4jlVboD7KKxk42aZ00606dRVIfEv6+Y3RtfvtS0W0laxNrdyRjzfN6K3faB1HcZxSzSxWILzMZZ25IJ+Zj6n0/wA4qpcauCStkmxf77dT/hWe5LkliSx6k1hOs3oCpJycrWv0K2o3M13OZJjk9AB0UegqoferU4wKz5n7CuZ3bO+DVrIxtSJSUoPunkVBbQl2yelas1t9oXp8w5FJFEEXFYyVhvQjjXbxViNcmmEc8VYgWpQmwMdV5lFaLqAlUZ8c02iYu5m3eFXiq1s8sUyyQSPHIvIZDgj8afcsWc1LZx9zS2LOo0jx3qdkAl6qXkY7t8r/AJj+orrtL8caRekJM72kh4xMPl/76HH54rzXyFYciq8trjpXTDF1IdbnNUwlKfSx7zHIkqB42V0bkMpyDTq8N0rVdR0eTdZTsi90PKn8K9A8O+OLa+KwaiFtrg8Bv4G/wrupYuE9Hozgq4OcNVqjsqKAQRkciiuo5AooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiigkAEk4AoAq6nfQadYy3V022KMZPqfQD3NeLa5qtzrmpPczkgdETPCL2ArW8beIG1m+8i3Y/YYGIXB++f73+H/ANesa3i44FeTiq/O+WOyPXwmH9muaW7HWTPazxzRHEkbBgfevQLK4S/23mnSBZ1AEkZ/kR/I/wD6q4NoyvanW88ttMssDtHIvRlNY0qrps2rUVVR6IbpS5+1Wrxk91G8fpz+lN8/Tc/NNEp9GO3+dYmneJnkUrewK5H8afKT+FXl1uxb70Uyn2AP9a744hNXOR0JrSxpRz6Ypz59rj/rotW01DTgPklRv9xS38hWJ/a9j2SY/wDAR/jR/alqfuwyn6kCq+sIiVCT6Glc38EisiW8syMCCCgAIPY7sVg+FrbVNL0G2sJDbtJEXzJ8zZBYsOOOmcdaln1nZxDbIPdzmqM2s3r5AkEY9EUD9etZSrq9zohTqcjp9G0/uv8A5m49vORvu7yUKP8Ab8tR+WP51Tl1PSLL5vM8+Udohk/99H/GsCWWSVt0rs59WOayWGGI9DisamIl0LWFS3Z1Vx4hnmTFoi28Z7jlvzrKaRnctIzMx6ljk1Ss5MEoe/Iq0TWfO56s6IQjBe6ixG+KseYMVnB8Gp48vTRE4izMW4FV/ILnmr6w5qTytop2JjKxSSMIKo3wCNuHQ/zrRuDtBrPf96Sp6Gpkr6Gy1K8Yya0rVMjJqpFCVfae1aUShUrOKM5shuvlWsi7lCqfWr99KOaw7ly78UpbjgiEAu/41pW6YUVXtouhrQiWpLY9FwKhlHNWGOBVduTQxIZtB6ioJrcHkcGrSilYcUh3NXw14rvdK2W9zm4swcbWPzIPY/0r0vTNUtNTiD2kyscZKnhh9RXjqxg9etXbKWS3lV4XZHHQqcEV2UcVKGj1Rx18LGpqtGex0VyOi+JZdojvlMg/56L1/Ed66qCaOeMPEwZTXpQqRmro8ypSlTdmSUUUVoZhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFBIAJJwBQAVwHxI8SG3jbSrJ8SOv79wfuqf4fqe/t9aTxZ422l7PRXBPR7kfyX/H8vWvPnR5WLuSzE5JJySa8/E4pW5IHo4XCu6nMZbyAMN1atrIuRWK8bIelSwTlDzXnHpM6bYrpmq8kGM4FQWd2pHJrSSWNx1FXozN3iUbZSsxGO1W+9TJGhcEYpXiweKuMbIuMrjYxmrKjAqKJasKpxVJETZDKKqt1q7KhxVR1IoZUGMrOuBiZ/rWjVG7GJj7is57GjIVJVgR1FaCkSIGU9az6sWbFX2n7p/nUQdmIshMVag6gU1Y/WpVISt0hS1L8aYUVHOwUVALoAdahd2lPHSqucvK09SCd95IFMjiwc4q0kGOvWpVixyamxvGViIQgrnuKgmnCqRmrsjBBWJqZPLp+IpTVtg5ebUqXs+SQDVWJNzZNNALtVyJMAVgyySJcVaQYFRxLT5PlWhEsZI1QhwWxTZ5MCooPmOaCi2KXGaQCpAvFAhFFWbdCTzTYUNaNpbliMCrjG5E5WRasISzCuw0mJowCMisrSrM8Eiult49igV6dCnbU8yvUvoWQciigUV1nGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV514/8AFW4y6VpzcD5biUd/VB/X8q1/HviQ6TbCzs2/06Zc7h/yzX1+vpXl8ERY7m5J55rgxeIt7kfmehg8Pf8AeS+QkERPJq7GgxSAADinKcV5h6YPCrDkVTmsyOUq+GpaYjF2vGe4qVLmRO5rRdFbqKha2Q0XGOtL9/NQZ6nFav2kmsq3tlEyH3rT8oVpBgkWYZxVkTCqUUQqysYrVMymtRzTAioJGyeKkZAKhbg0myoIQITVW6hJkB9qu7xUF1MFK/SpklYt3K6W/rUuESq0t2qjrVSS83dDWV0tibNm1FdKRt7io5Z6wxLIWBXgita2HmoGPXuK0jK+jKSHKWZvatG3wBVZUx0qxDweatCmrlyJQTk0TkKKjMu0VWnnyKq5gou5BcynNUZSSpqww3moZcLWcnY6FsUViCtmrCLnoKRRuarsCBV5FYpXE3YiUbRUEz1NcPjIFZ08meBTfYEiORt74FW4EwBUNrAScmr6R0htiotSrGTTo4ye1aFnbbiMirjG5lKVhlrbkkV0OmWeSOKLGxyRxxXRWdsqAcV3UaPU4q1bsSWcARRxV0DFIq4FOrvSsee3dhRRRTEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVfUbuKwsZ7qc4jiUsff2/HpViuG+Kd/5Vja2KEgzMZHA/ur0B/E/pWdWfs4ORpRp+0monBXk8upX813cHMkrFj7ew9hUqpgYqC24Aq0DXhN3d2e8lbRCbKQoasRgMKk8qiwrlLaaOcVc8r2ppi9qLBzGc6yDOOah82VOoNa3lCmtCp6inYdylZ3JadARWn561HbWqebnHap3txWkFoUmPhnXNWFuFqrHbj1qdbcetWjOYSTjFVXnyasSQDFQ+SM0McEQmU1n6i8jSqFz92tgRL6VUu0AlHHaonsWZAhdvvVNHBjrVvFNNY3EEcY9KsRN5bAj8ahXIp/Qc00JmmjKy5ByDQ0mKy0uxE3qp61Z3+YAQcg1spXGtSZps8ZpuC1R4C8k0158DAockgsSSSBBgdaqHMjU8I0h9qsRxBBk1m7yJbsNiiCjJollC9KSaUAYFUZZOfehu2wkr6sS4lzmo4Ii7ZIpAoOXkYKg6ljgVcspIpXmjjOWhbY3HfAP+foakq5Yhi4HFWo4skcU+CLIFadraFiOK1hC5jOdiC2tSx6Vt2Nn04qzZWOMZFa8FuEHSu2lROKpWGW8IQDir8QqMLU0YxXZFWOSTuSUUUVZmFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5F8R7tbnxO8anIgjWL8ep/nXqWq3qadp1zdy42woWx6nsPxNeCXM8lzcyzysWkkYux9STmuHGztFQO/AQvJzL0AAUVMDWWkzL3qwlyO9eZY9Q0on21ZSUGspbhfWpFuF9aE7CcbmvGyk1KVXFY63I/vVKLrj71WpEOBolFpNi1n/aveg3eO9HMg5WasMagkj0pzIKz7W73BznvUwnLGtIvQqKZcRBTjgVXSQ4pwc1VxNCuRioT1pXao81JcUOqjdN++NXQCaz5lzKx96iew2IuDS7RSKh7U7y2NZkiZAqKQkjAqcRE9acIhRqF0URFk81Yi3IuB0qfYopwC+1NIOYhwzdafHDzk1IWA6VG8oA60aCu2T71QVWmuM9KryzZOBTVRpD0ovcEgdy1RRskkkscZEk0a7jGDz9K07a07sKzo43tpbOKKF5LuKd1aNQAXibJLZOBj7p69RimokuVivb3QeFkvYvPjkjU7Y4SV385jz0JGB361f8ADls0siSRQukIhEZZ0K7yGO3APsTz71u2OgIJ97ySvGJDIkTEbEYnJPAyeSepOO1dNaaeBj5a3hRbMJ1kjPsbDOMit+0slUDirFvahe1Xo0AHArup0kjhqVWxkUQUdKlxTwKQiui1jnvcQVIgpqipAMU0JhRRRTEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRVbUryOwspbmX7qDOPU9hSbsrsaV3ZHCfE/Vt5j0uFumJJcfoP61wSQcc1o3zSXl9NcznMkjFjTdmK8StUdSbke7RpqnBRM57c9qi8l/StUj2owKyuamV5TjsaNr+hrYWMHtQ0I9KLhcyAr+9SIrn1rS8oelHlj0ouFygI3p4iY9aviEntS+QfSjULoLGMLFgnknNXFUCqoiZelOG4VakHMXAaUGqysfWl8zHeq5guixgmmMQKYJuOtVpZSTxQ5JApFpp1UVSMmTmoySeppDxWblcCdJQKcZhVUsKjMopXYrFwzUwyk1UMx7CkDO3QUahZFsye9J5uKjjhkarUdn600hNpFcyE9KTy3c+1aKWijtVhLb2pqIuYzI7XByavwW4wMCrkdoWPStG1sCccVpGm2ZyqJFO3tiSOK17SxJAyKvWdgAQSK1o4AoGBXXTo9zjqVuxQgtQuOK0YY8U9YvarCR4rqjCxyyncREqULSgYpa1SMmwxSEUtFMQAYooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACk60tFAATiuL8W3D3coiQnyY+g9T612MwJQgd652/stzE4rCum42Rvh2oyuzgpbcqTkVXePHausudPPPFZ0tiR2ry5Umj1I1UzAK03aa1ZLQjtURt8dqzcGa86KSHFKWzVloaiaKlYdyLNOUikKH0oCGkBOrgUvmDNQbTShCadxWJzIKjLjNM2GkKEUXHZDi9MZjShaUr7UARZNJtz1qUDPanrETSsO5Btp3lgirIh9qkSE+lPlFcoeSKaLdc9K1Rak1MlnzyKpQZPOkZS2wx92p0t8dq1ktPap0sie1UqTIdVGVHD7VZjgJ7VqRaexPSrsWn46itY0WZSrIyYrUntV2GxJ7VrQ2qr2q1HDjoK3jRMJVijb2KqORV+KADoKsRwmrKQ4rojTsc8qlyGGI1aSMAU9VxTq2UbGLlcQKBS0UVRIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAARmoZIVbqKmootcadihNZKw6VRm05T2rdxTCoNZummWqjRy82lj0qnNpXoK7Joge1RNbg9qylQTNY12jhZdNI7VVksCP4a717NT2qCSwU/w1i8MbRxJwZssdqaLP2rspdPH92oTYAfw1k8OarEHIm0welJ9mx2rrDYA/w1G2nD+7S9gyvbo5cW+e1O+yZ7V0f9ngH7tOWw9qXsQ9uc19kPYUG0J7V1S6f7VINPH92q+rsX1g5FbE56VLHZnPSuqOn/7NC2OP4aaw4niLnOi0NSJZEmuiSxz2qwlj7VaoGbrnPx2R9Ksx2JPaugjswO1TrbAdq1VAzdcxIdPHcVcjslXqK01hA7VIIhWqpJGLqtlBbdR0FL5Ga0AgpQoq+RE85RjtvWrCQgVOBRTUUiXJsaqAU7FFFUSFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABik2ilooAjaIGozbj0qxRSsh3ZV+zCkNqPSrdFLlQ+ZlL7IKctqB2q3RRyoOZlYW4p4hFTUU7IXMyLyR6UnkipqKLILkYiApwQelOoosFxAoFLRRTEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The vas sheath is sutured over the prostatic vasal end.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_63_38910=[""].join("\n");
var outline_f37_63_38910=null;
var title_f37_63_38911="True knot";
var content_f37_63_38911=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71345&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71345&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tight true knot",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 246px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drucilla J Roberts, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_63_38911=[""].join("\n");
var outline_f37_63_38911=null;
